GSK plc 6-K, filed May 1, 2024
GSK plc (GSK)
6-K
2024-05-01
For: 2024-05-01
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on May 1, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
|
|
|
|
|
GSK makes a strong start to 2024 with improving outlook for the
year
|
||
|
|
|
|
|
Broad-based performance drives sales, profits and earnings
growth:
|
||
|
●
|
Total
Q1 2024 sales £7.4 billion +10% and +13% ex
COVID
|
|
|
●
|
Vaccines
sales +16%, +22% ex COVID. Shingrix £0.9
billion +18%, Arexvy £0.2
billion
|
|
|
●
|
Specialty
Medicines sales +17%, +19% ex COVID with HIV
+14%
|
|
|
●
|
General
Medicines sales +1%. Trelegy £0.6
billion +33%
|
|
|
●
|
Total
operating profit and Total EPS for Q1 2024 reflected higher charges
for CCL(2)
remeasurement, partly offset by strong Core(1)
growth
|
|
|
●
|
Core
operating profit +27% (with further positive impact of +8% ex
COVID) and Core EPS +28% (with further positive impact of +9% ex
COVID). This reflected strong sales and SG&A leverage, partly
offset by increased investment in R&D and lower royalty
income
|
|
|
●
|
Cash
generated from operations exceeded £1 billion with free cash
flow of £0.3 billion
|
|
|
(Financial Performance – Q1 2024 results unless otherwise
stated, growth % and commentary at CER, ex COVID is excluding
COVID-19 solutions as defined on page 47).
|
||
|
|
||
|
|
Q1 2024
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
Turnover
|
7,363
|
|
6
|
|
10
|
|
Turnover ex COVID
|
7,362
|
|
8
|
|
13
|
|
Total
operating profit
|
1,490
|
|
(28)
|
|
(18)
|
|
Total
operating margin %
|
20.2%
|
|
(9.7ppts)
|
|
(7.8ppts)
|
|
Total
EPS
|
25.7p
|
|
(30)
|
|
(19)
|
|
Core
operating profit
|
2,443
|
|
17
|
|
27
|
|
Core
operating margin %
|
33.2%
|
|
3.1ppts
|
|
4.6ppts
|
|
Core
EPS
|
43.1p
|
|
16
|
|
28
|
|
Cash
generated from operations
|
1,126
|
|
>100
|
|
|
|
|
|
|
R&D delivery and targeted business development supports future
growth:
|
|
|
●
|
Strong
pipeline progress with positive phase III read outs for gepotidacin
in uncomplicated urogenital gonorrhoea, Cabenuva in HIV
treatment, Jemperli in
endometrial cancer, and Blenrep in multiple
myeloma
|
|
●
|
Innovative
Vaccine portfolio further strengthened with regulatory submission
acceptances for Arexvy for
prevention of RSV in adults 50-59 (US), new meningococcal ABCWY
vaccine candidate (US), and Shingrix for prevention of shingles in
at-risk adults >18 (China)
|
|
●
|
US FDA
Fast Track designation received for bepirovirsen in chronic
hepatitis B
|
|
●
|
New
positive data for CAB-ULA as ultra long-acting treatment for HIV
supports progression and transition of HIV portfolio for long-term
growth
|
|
●
|
US FDA
regulatory submission accepted for priority review for Jemperli to treat endometrial cancer in
broader patient populations
|
|
●
|
Acquisition
of Aiolos Bio completed, expanding respiratory biologics pipeline
with AIO-001, a potentially best-in-class long-acting TSLP
monoclonal antibody for treatment of asthma
|
|
|
|
|
2024 guidance updated and dividends:
|
|
|
●
|
Now
expect 2024 turnover growth towards the upper part of 5% to 7%
range; Core operating profit growth of 9% to 11% (previously 7% to
10%); Core EPS growth of 8% to 10% (previously 6% to
9%)
|
|
●
|
Dividend
declared of 15p for Q1 2024; 60p expected for Full Year
2024
|
Guidance all at CER and excluding COVID-19
solutions
|
|
|
Emma Walmsley, Chief Executive Officer, GSK:
“We
have made a strong start to 2024, with another quarter of excellent
performance and continued pipeline progress, including positive
data read outs for 4 phase III medicines. These, together with
other R&D achievements, mean we have strengthened prospects for
growth in all of our key therapeutic areas this quarter: infectious
diseases, HIV, respiratory/immunology and oncology. We expect this
strong momentum to continue, and look forward to delivering another
year of meaningful growth in sales and earnings in
2024.”
|
The Total results are presented in summary above and on page 8 and
Core results reconciliations are presented on pages 20 and 21. (1)
GSK has made an update to its reporting framework in Q1 2024 which
is to change the description of Adjusted results to Core results to
align with European peers in the pharmaceutical industry but with
no change to the basis or figures. Core results are a non-IFRS
measure that may be considered in addition to, but not as a
substitute for, or superior to, information presented in accordance
with IFRS. The following terms are defined on page 47: Core
results, £% or AER% growth, CER% growth,COVID-19 solutions,
turnover excluding COVID-19 solutions; and other non-IFRS measures.
GSK provides guidance on a Core results basis only, for the reasons
set out on page 18. All expectations, guidance and targets
regarding future performance and dividend payments should be read
together with ‘Guidance and outlooks, assumptions and
cautionary statements’ on page 49. (2) Contingent
consideration liability is abbreviated to CCL.
2024 Guidance
GSK
provides its full-year guidance at constant exchange rates (CER).
All expectations and full-year growth rates exclude any
contributions from COVID-19 solutions.
GSK has
started 2024 strongly, with business momentum across all product
areas, particularly in Vaccines and Specialty Medicines, including
sales contributions from newly launched vaccines and medicines
Arexvy and Ojjaara respectively. General
Medicines, particularly Trelegy, also performed better than
expected. Along with a favourable product mix, GSK benefitted in
the quarter from a successful Zejula royalty dispute appeal, and we
also expect royalty income to be slightly higher for the full year.
As a result, GSK has upgraded its full-year 2024
guidance.
|
|
|
|
|
All Guidance excludes the contributions of COVID-19
solutions
|
Current 2024 guidance at CER
|
Previous 2024 guidance at CER
|
|
Turnover
|
Increase
towards the upper part of the range of between 5% to
7%
|
Increase
between 5% to 7%
|
|
Core
operating profit
|
Increase
between 9% to 11%
|
Increase
between 7% to 10%
|
|
Core
earnings per share
|
Increase
between 8% to 10%
|
Increase
between 6% to 9%
|
GSK
expects first half 2024 sales growth to be higher than second half
2024 due to the comparator to H2 2023, which benefitted from newly
launched vaccines and medicines. In particular, second half 2024,
compared to the same period in the prior year, is expected to be
influenced by the 2023 launch dynamics and initial channel
inventory build attributable to Arexvy. In addition, we expect the
majority of Shingrix sales
in China in to be in the first half 2024.
This
guidance continues to be supported by the following turnover
expectations for full-year 2024 at CER:
|
|
|
|
All turnover expectations exclude the contributions of COVID-19
solutions
|
No change to current 2024 expectations at CER
|
|
Vaccines
|
Increase
of high single-digit to low double-digit per cent in
turnover
|
|
Specialty
Medicines
|
Increase
of low double-digit per cent in turnover
|
|
General
Medicines
|
Decrease
of mid-single-digit per cent in turnover
|
Core
Operating profit is expected to grow between 9 to 11 per cent at
CER (previously 7 to 10 per cent increase), despite a 6 percentage
point impact to Operating Profit growth following the loss of the
majority of Gardasil royalties effective from the beginning of
2024. GSK continues to expect to deliver leverage at a gross margin
level due to improved product mix from Vaccines and Specialty
Medicines growth and continued operational efficiencies. In
addition, GSK continues to anticipate further leverage in Operating
Profit due to a step down in SG&A growth to a low single-digit
increase. R&D continues to be expected to increase broadly in
line with sales to support growth of the pipeline.
Core
Earnings per share is now expected to increase between 8 to 10 per
cent at CER, reflecting higher operating profit and more favourable
net finance costs. Expectations for non-controlling interests
remain unchanged relative to 2023, and GSK continues to anticipate
an increase in the Core effective tax rate to around 17% following
implementation of a global minimum corporate income tax rate
aligned with the Organisation for Economic Co-Operation and
Development ‘Pillar 2’ initiative.
2021-26 and 2031 Outlooks
In
January 2024 GSK set out improved outlooks for the period 2021-2026
and for 2031. Please see 2023 Full year and fourth quarter results
on gsk.com.
Additional commentary
Dividend policy
The
Dividend policy and the expected pay-out ratio remain unchanged.
Consistent with this, and reflecting strong business performance
during the quarter, GSK expects to declare a dividend for Q1 2024
of 15p per share and for the full year 2024 60p.
COVID-19 solutions
For the
full year 2024, GSK does not anticipate any further COVID-19
pandemic-related sales or operating profit. Consequently, and in
comparison to 2023, it is anticipated that the full year growth in
sales and Core operating profit will be adversely impacted by one
and two percentage points, respectively.
Exchange rates
If
exchange rates were to hold at the closing rates on 31 March 2024
($ 1.26/£1, € 1.17/£1 and Yen 191/£1) for the
rest of 2024, the estimated impact on 2024 Sterling turnover growth
for GSK would be -3% and if exchange gains or losses were
recognised at the same level as in 2023, the estimated impact on
2024 Sterling Core Operating Profit growth for GSK would be
-5%.
Results presentation
A
conference call and webcast for investors and analysts of the
quarterly results will be hosted by Emma Walmsley, CEO, at 12 noon
BST (US EST at 7am) on 1 May 2024. Presentation materials will
be published on www.gsk.com prior to the webcast and a transcript
of the webcast will be published subsequently.
Notwithstanding
the inclusion of weblinks, information available on the
company’s website, or from non GSK sources, is not
incorporated by reference into this Results
Announcement.
|
|
|||||
|
Performance:
turnover
|
|||||
|
|
|
|
|
|
|
|
Turnover
|
Q1 2024
|
||||
|
|
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
Shingles
|
945
|
|
13
|
|
18
|
|
Meningitis
|
299
|
|
7
|
|
11
|
|
RSV
(Arexvy)
|
182
|
|
–
|
|
–
|
|
Influenza
|
13
|
|
8
|
|
8
|
|
Established
Vaccines
|
838
|
|
3
|
|
7
|
|
Vaccines ex COVID
|
2,277
|
|
17
|
|
22
|
|
Pandemic
vaccines
|
–
|
|
>(100)
|
|
>(100)
|
|
Vaccines
|
2,277
|
|
12
|
|
16
|
|
HIV
|
1,613
|
|
10
|
|
14
|
|
Respiratory/Immunology
and Other
|
635
|
|
6
|
|
11
|
|
Oncology
|
273
|
|
>100
|
|
>100
|
|
Specialty Medicines ex COVID
|
2,521
|
|
14
|
|
19
|
|
Xevudy
|
1
|
|
(97)
|
|
(97)
|
|
Specialty Medicines
|
2,522
|
|
13
|
|
17
|
|
Respiratory
|
1,725
|
|
(2)
|
|
2
|
|
Other
General Medicines
|
839
|
|
(7)
|
|
(2)
|
|
General Medicines
|
2,564
|
|
(4)
|
|
1
|
|
Total
|
7,363
|
|
6
|
|
10
|
|
Total ex COVID
|
7,362
|
|
8
|
|
13
|
|
By Region:
|
|
|
|
|
|
|
US
|
3,589
|
|
10
|
|
14
|
|
Europe
|
1,621
|
|
(5)
|
|
(3)
|
|
International
|
2,153
|
|
9
|
|
16
|
|
Total
|
7,363
|
|
6
|
|
10
|
|
|
|||||
|
Turnover ex COVID is excluding COVID-19 solutions during the years
from 2020 to 2023 and is a non-IFRS measure defined on page 47 with
the reconciliation to the IFRS measure Turnover included in the
table above. Financial Performance – Q1 2024 results unless
otherwise stated, growth % and commentary at
CER.
|
|||||
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Vaccines
|
Total
|
2,277
|
12%
|
16%
|
|
Excluding COVID
|
2,277
|
17%
|
22%
|
|
In Q1 2024, Vaccine sales increased by double-digits, reflecting US
demand for Arexvy and strong market growth for Shingrix in International and European markets. However,
the quarter's growth was adversely impacted by six percentage
points due to COVID-19 solution sales compared to Q1
2023.
|
|
|
|
|
|
Shingles
|
945
|
13%
|
18%
|
The
sales of Shingrix, a
vaccine against herpes zoster (shingles), increased in the quarter
due to strong demand following public funding expansion in
International and European markets, with new national immunisation
programmes in Australia and Europe, including the UK, together with
earlier than anticipated supply to Zhifei (Chongqing Zhifei
Biological Products, Ltd), GSK’s co-promotion partner in
China. Markets outside the US now represent more than 50% of global
sales (Q1 2023: 40%), with Shingrix launched in 39 countries. The
majority of these markets have average cumulative immunisation
rates below 5%.
In Q1
2024, US sales decreased by 7% at AER and 4% at CER, reflecting the
comparison to Q1 2023, which benefitted from the removal of adult
vaccine cost-sharing covered under Medicare Part D and expanded
coverage of adult vaccines under Medicare following the
implementation of the Inflation Reduction Act. In addition, the
performance reflected the prioritisation of other adult vaccines
for example, influenza and COVID-19 during the viral respiratory
season and the increasing challenge of activating harder to reach
consumers. The US cumulative immunisation penetration rate at the
end of 2023 reached 37% of the more than 120 million US
adults(1)
currently recommended to receive Shingrix, up seven percentage points
since the end of 2022. The US performance in Q1 2024 was partly
offset by favourable pricing and prior period channel inventory
movements.
|
(1)
|
United States Census Bureau,
International Database, Year 2023.
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
£m
|
AER
|
CER
|
|
Meningitis
|
299
|
7%
|
11%
|
In Q1
2024, meningitis vaccine sales increased following higher demand in
International markets for Menveo, a vaccine against meningitis
ACWY. Sales for Bexsero, a
vaccine against meningitis B, were stable at AER and increased by
3% at CER in the quarter, primarily reflecting increased demand in
Australian regional immunisation programmes and the recent launch
in Vietnam. However, this performance was partly offset by tender
phasing in Europe.
|
|
|
|
|
|
RSV (Arexvy)
|
182
|
–
|
–
|
Arexvy, a respiratory syncytial virus (RSV) vaccine for
older adults, delivered Q1 2024 sales of £182 million,
reflecting continued strong consumer uptake and leading market
share. In the US, Q1 2024 sales were £154 million, with the
overwhelming majority of doses administered in the retail setting.
Arexvy maintained around
two-thirds of the vaccination share, while demand decreased overall
in line with anticipated seasonality patterns. More than seven
million of the 83 million US adults(1) aged 60 and older
at risk have been protected by Arexvy since the launch in Q3 2023. The
performance in Q1 2024 also reflected initial tender deliveries in
Saudi Arabia, continued consumer uptake in Canada, and a new launch
inventory build in Brazil.
|
|
|
|
|
|
Established
Vaccines
|
838
|
3%
|
7%
|
In Q1
2024, Established Vaccines' growth was driven by an increased
supply of measles, mumps, rubella, and varicella vaccines in
International, a higher share of Rotarix in the US and increased demand
in International. Infanrix/Pediarix decreased due to
competitive pressure in the US.
|
|
|
|
|
|
|
Specialty Medicines
|
Total
|
2,522
|
13%
|
17%
|
|
Excluding COVID
|
2,521
|
14%
|
19%
|
Specialty Medicines sales increased by double digits in the
quarter, reflecting continued growth across disease areas, with
strong performances in HIV, Respiratory/Immunology and
Oncology.
|
|
|
|
|
|
HIV
|
1,613
|
10%
|
14%
|
In Q1
2024 HIV delivered double digit growth, which was primarily driven
by a 2 percentage point increase in market share versus Q1 2023 as
a result of strong patient demand for Oral 2DR (Dovato, Juluca) and long-acting medicines
(Cabenuva, Apretude), as well as favourability in
the quarter on pricing and tender phasing.
|
|
|
|
|
|
Oral
2DR
|
640
|
17%
|
21%
|
Oral
2-drug regimens sales in the quarter were £640 million, which
now represents 40% of the total HIV portfolio. Dovato continues to be the highest
selling product in the HIV portfolio with sales of £483
million in the quarter and growing 27% versus Q1 2023.
|
|
|
|
|
|
Long-Acting
Medicines
|
267
|
77%
|
83%
|
Long-Acting
Medicine sales in the quarter were £267 million, growing
£116 million at AER; £125 million at CER versus Q1 2023
and now represent 17% of the total HIV portfolio compared to 10%
for Q1 2023. Cabenuva sales
in Q1 2024 were £213 million and growing 73% driven by strong
patient demand. Apretude
sales in Q1 2024 were £54 million, growing £30 million at
AER; £32 million at CER compared to Q1 2023.
|
|
|
|
|
|
Respiratory/Immunology and Other
|
635
|
6%
|
11%
|
Sales
primarily comprise contributions from Nucala in respiratory and Benlysta in immunology. In Q1 2024,
sales growth for Nucala and
Benlysta increased, mainly
driven by demand in European and International markets. However,
this performance was reduced by the US, where the growth of the
medicines remained broadly stable. Volume demand growth was partly
offset by the impact of channel inventory reduction following a
channel inventory build in Q4 2023.
|
|
|
|
|
|
Nucala
|
374
|
8%
|
13%
|
Nucala, is an IL-5 antagonist monoclonal antibody treatment
for severe asthma, with additional indications including chronic
rhinosinusitis with nasal polyps, eosinophilic granulomatosis with
polyangiitis (EGPA), and hypereosinophilic syndrome (HES). In Q1
2024, sales growth was driven by strong performances in Europe and
International regions, which reflected higher patient demand for
treatments addressing eosinophilic-led disease.
|
|
|
|
(1)
|
United States Census Bureau,
International Database, Year 2023.
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
£m
|
AER
|
CER
|
|
Benlysta
|
260
|
3%
|
8%
|
Benlysta, a monoclonal antibody treatment for Lupus,
continues to grow consistently, representing strong demand and
volume growth in European and International markets. Bio
penetration rates have increased in certain International markets,
particularly in Japan and China.
|
|
|
|
|
|
Oncology
|
273
|
>100%
|
>100%
|
In Q1
2024, Oncology sales growth increased driven by strong patient
growth for Zejula, a
PARP(1),
Jemperli, a
PD-1(2)
blocking antibody, and Ojjaara/Omjjara, a daily JAK1/JAK2 and
ACVR1(3)
inhibitor. Jemperli, a
medicine for front-line treatment in combination with chemotherapy
for patients with dMMR/MSI-H primary advanced or recurrent
endometrial cancer, continued to grow strongly and delivered sales
of £80 million in the quarter. Ojjaara/Omjjara, a treatment for
myelofibrosis patients with anaemia, launched in the US in Q3 2023
and in the UK and Germany in Q1 2024, has seen strong uptake since
launch and delivered £52 million of sales in the
quarter.
|
|
|
|
|
|
Zejula
|
141
|
24%
|
27%
|
Zejula delivered double-digit sales growth in the quarter,
with strong performances across all regions following increased
patient demand and higher volumes. In addition, new launches,
particularly in the International region, also contributed to the
performance.
|
|
|
|
|
|
General Medicines
|
2,564
|
(4%)
|
1%
|
Sales include contributions from both the Respiratory and Other
General Medicine portfolios. In Q1 2024, sales decreased 4% at AER
but increased by 1% at CER. This increase was driven primarily by
strong demand across all regions for Trelegy, a chronic obstructive pulmonary disease (COPD)
and asthma medicine. The performance also included increased growth
for Anoro in Europe and International, and a strong
antibiotic performance in International markets. However, this
performance was primarily offset by a decrease across the
Established Respiratory and Other General Medicine portfolios
following the adverse impact of removing the Average Manufacturer
Price (AMP) cap on Medicaid drug prices in the US. This removal
particularly impacted the performance of Advair, Flovent, and Lamictal in the quarter due to significant pricing
reductions, reduced commercial contracting, and the decision to
discontinue branded Flovent. However, the increased use of authorised generic
versions of Advair and Flovent has partially offset the impact of AMP cap removal
while, significantly, continuing to provide access to
patients.
|
|
|
|
|
|
Respiratory
|
1,725
|
(2%)
|
2%
|
In Q1
2024, the increase in sales growth reflected Trelegy's strong performance in all
regions and the increased demand for Anoro, particularly in Europe and
International. However, as mentioned above, this was partially
offset by the decrease across the Established Respiratory portfolio
and the removal of the AMP cap.
|
|
|
|
|
|
Trelegy
|
591
|
27%
|
33%
|
Trelegy is the most prescribed single inhaler triple therapy
(SITT) treatment worldwide for COPD and asthma. In Q1 2024 sales
growth significantly increased across all regions, reflecting
strong patient demand, single-inhaled triple therapy class growth,
and increased market share.
|
|
|
|
|
|
Seretide/Advair
|
282
|
(17%)
|
(13%)
|
Seretide/Advair is a combination treatment used to treat
asthma and COPD. In Q1 2024, the decrease in sales reflected
continued generic erosion from competitor products in Europe and
International and the removal of the AMP cap on Medicaid drug
prices in the US.
|
|
|
|
|
|
Other General Medicines
|
839
|
(7%)
|
(2%)
|
The
performance in Q1 2024 was adversely impacted by ongoing generic
competition and the removal of the AMP cap on Medicaid drug prices
in the US, notably impacting Lamictal's performance. This
performance was partially offset by increased antibiotic growth in
International markets.
Footnotes:
|
(1)
|
PARP: a Poly ADP ribose
polymerase
|
|
(2)
|
PD-1: a programmed death receptor-1
blocking antibody
|
|
(3)
|
JAK1/JAK2 and ACVR1: once a-day,
oral JAK1/JAK2 and activin A receptor type 1 (ACVR1)
inhibitor
|
By Region
|
|
|
|
|
|
|
|
Q1 2024
|
|||
|
|
£m
|
AER
|
CER
|
|
|
US
|
Total
|
3,589
|
10%
|
14%
|
|
|
Excluding COVID
|
3,589
|
10%
|
14%
|
Vaccine
sales increased by double-digits in Q1 2024, driven by continued
strong consumer uptake and Arexvy's leading market share. The
decrease in Shingrix sales
reflected the comparison to Q1 2023, the prioritisation of other
adult viral respiratory season vaccines, and the increasing
challenge of activating harder to reach consumers. Favourable
pricing and a prior-period channel inventory reduction partly
offset this performance.
In Q1
2024, the sales of Specialty Medicines increased, driven by strong
HIV and Oncology performances. However, despite increased patient
demand, the performances of Nucala and Benlysta remained broadly stable in the
quarter, reflecting the impact of channel inventory
reductions.
General
Medicine’s growth in Q1 2024 was driven by increased demand
for Trelegy and the growth
of the SITT market. However, this performance was offset by
Established Respiratory and Other General Medicines following the
removal of the AMP cap on Medicaid drug prices, which particularly
impacted Advair,
Flovent, and Lamictal.
|
|
|
|
|
|
|
Europe
|
Total
|
1,621
|
(5%)
|
(3%)
|
|
|
Excluding COVID
|
1,621
|
1%
|
3%
|
In Q1
2024, Vaccine sales growth excluding COVID-19 solutions was broadly
stable despite Shingrix
growth across several markets following new national immunisation
programmes. Lower Bexsero
tender deliveries partly offset this performance.
Specialty
Medicines sales increased by a double-digit percentage due to the
performance in HIV and Oncology. The performance of Benlysta in immunology and Nucala in respiratory, including the
impact of new indication launches, also contributed to the sales
increase.
General
Medicines sales were broadly stable in the quarter, reflecting
strong growth in Trelegy
and Anoro, offset by a
decrease in Established Respiratory.
In Q1
2024, COVID-19 solutions adversely impacted growth by six
percentage points. Excluding this impact, European sales increased
by 3% at CER.
|
|
|
|
|
|
|
International
|
Total
|
2,153
|
9%
|
16%
|
|
|
Excluding COVID
|
2,152
|
11%
|
18%
|
In Q1
2024, sales excluding COVID-19 solutions increased 11% at AER and
18% at CER, which reflected year-on-year exchange movements in
several International markets compared to Q1 2023.
Vaccines'
double-digit growth was driven by the expansion of public funding
for Shingrix in Australia
and Japan, together with earlier than anticipated supply to Zhifei,
GSK’s co-promotion partner in China. Established vaccines
also contributed to growth due to increased demand and supply
phasing.
Specialty
Medicine’s double-digit growth was driven by HIV,
Nucala in Respiratory,
Benlysta in Immunology, and
Zejula in
Oncology.
General
Medicines sales were broadly stable, with Trelegy and Antibiotics delivering
growth offset by a decrease in Other General Medicines and
Established Respiratory.
In Q1
2024, COVID-19 solutions adversely impacted growth by two
percentage points. Excluding this impact, International sales grew
18% in Q1 2024.
|
|
|
Financial
performance
|
|
|
|
|
|
|
|
|
Total Results
|
Q1 2024
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
Turnover
|
7,363
|
|
6
|
|
10
|
|
Cost of
sales
|
(1,970)
|
|
1
|
|
2
|
|
Selling,
general and administration
|
(2,087)
|
|
(3)
|
|
–
|
|
Research
and development
|
(1,434)
|
|
14
|
|
17
|
|
Royalty
income
|
151
|
|
(16)
|
|
(16)
|
|
Other
operating income/(expense)
|
(533)
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,490
|
|
(28)
|
|
(18)
|
|
Net
finance expense
|
(134)
|
|
(23)
|
|
(22)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,355
|
|
(29)
|
|
(18)
|
|
|
|
|
|
|
|
|
Taxation
|
(274)
|
|
|
|
|
|
Tax rate %
|
20.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,081
|
|
(34)
|
|
(23)
|
|
Profit
attributable to non-controlling interests
|
35
|
|
|
|
|
|
Profit
attributable to shareholders
|
1,046
|
|
|
|
|
|
|
1,081
|
|
(34)
|
|
(23)
|
|
|
|
|
|
|
|
|
Earnings
per share
|
25.7p
|
|
(30)
|
|
(19)
|
|
Financial Performance – Q1 2024 results unless otherwise
stated, growth % and commentary at CER.
|
|||||
|
|
|
Core results
Reconciliations
between Total results and Core results for Q1 2024 and Q1 2023, are
set out on pages 20 and 21.
|
|
|
|
|
|
|
|
|
|
Q1 2024
|
||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
Turnover
|
7,363
|
|
6
|
|
10
|
|
Cost of
sales
|
(1,733)
|
|
(1)
|
|
–
|
|
Selling,
general and administration
|
(1,979)
|
|
(4)
|
|
(2)
|
|
Research
and development
|
(1,359)
|
|
11
|
|
14
|
|
Royalty
income
|
151
|
|
(16)
|
|
(16)
|
|
|
|
|
|
|
|
|
Core
operating profit
|
2,443
|
|
17
|
|
27
|
|
|
|
|
|
|
|
|
Core
profit before taxation
|
2,310
|
|
20
|
|
32
|
|
Taxation
|
(404)
|
|
33
|
|
46
|
|
Core
profit after taxation
|
1,906
|
|
18
|
|
29
|
|
Core
profit attributable to non-controlling interests
|
154
|
|
|
|
|
|
Core
profit attributable to shareholders
|
1,752
|
|
|
|
|
|
|
1,906
|
|
18
|
|
29
|
|
Earnings
per share
|
43.1p
|
|
16
|
|
28
|
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Cost of
sales
|
Total
|
1,970
|
1%
|
2%
|
|
% of sales
|
26.8%
|
(1.2%)
|
(2.1%)
|
|
|
Core
|
1,733
|
(1%)
|
–
|
|
|
% of sales
|
23.5%
|
(1.7%)
|
(2.5%)
|
|
Total
and Core cost of sales as a percentage of sales decreased in Q1
2024 primarily driven by mix benefits from the growth in higher
margin Arexvy, Shingrix and Specialty products as well
as regional margin mix from higher US sales.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Selling,
general & administration
|
Total
|
2,087
|
(3%)
|
–
|
|
% of sales
|
28.3%
|
(2.5%)
|
(3.0%)
|
|
|
Core
|
1,979
|
(4%)
|
(2%)
|
|
|
% of sales
|
26.9%
|
(2.8%)
|
(3.3%)
|
|
Disciplined
SG&A investment to support global market expansion and disease
awareness for Arexvy and
Shingrix was more than
offset by a 6 percentage point favourable impact of the reversal of
the legal provision taken in Q1 2023 for the Zejula royalty dispute, following a
successful appeal. Total SG&A also included an increase in
significant legal costs reflecting increased legal fees (see
details on page 22).
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Research
&
development
|
Total
|
1,434
|
14%
|
17%
|
|
% of sales
|
19.5%
|
1.3%
|
1.0%
|
|
|
Core
|
1,359
|
11%
|
14%
|
|
|
% of sales
|
18.5%
|
0.9%
|
0.6%
|
|
In Q1
2024, R&D expense increased due to continued investment across
disease areas, including bepirovirsen (chronic hepatitis B) and the
advancement of clinical trial programmes associated with the
pneumococcal Multi Antigen Presenting System (MAPS) and mRNA in
Infectious Diseases.
In HIV,
early-stage research expenses increased following investment in
next-generation long-acting treatment and preventative medicines.
In Respiratory and Oncology, investment increased to support
lifecycle innovation and late-stage clinical development programmes
for depemokimab (asthma and eosinophilic inflammation), camlipixant
(refractory chronic cough), and Jemperli (endometrial cancer). Lower
R&D expenses predominately related to Arexvy in Infectious Disease and
Zejula and Ojjaara in Oncology partly offset
this.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Royalty
income
|
Total
|
151
|
(16%)
|
(16%)
|
|
|
Core
|
151
|
(16%)
|
(16%)
|
The
decrease in Total and Core royalty income in Q1 2024 is primarily
related to the cessation of the majority of Gardasil royalties at
the end of 2023, with Q1 2024 Gardasil royalties of £22
million (Q1 2023: £71 million). This was partly offset by
increases in Kesimpta and Biktarvy royalties.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Other
operating
income/(expense)
|
Total
|
(533)
|
>(100%)
|
>(100%)
|
In Q1
2024 other operating expense reflected a charge of £685
million (Q1 2023: £271 million credit) arising from the
remeasurement of contingent consideration liabilities primarily
reflecting improved longer term HIV prospects and foreign currency
movements and the liabilities for the Pfizer, Inc. (Pfizer) put
option. This was partly offset by a fair value gain of £57
million (Q1 2023: £65 million loss) on the retained stake in
Haleon plc (Haleon) and other net income of £95 million (Q1
2023: £91 million).
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Operating
profit
|
Total
|
1,490
|
(28%)
|
(18%)
|
|
|
% of sales
|
20.2%
|
(9.7%)
|
(7.8%)
|
|
|
Core
|
2,443
|
17%
|
27%
|
|
|
% of sales
|
33.2%
|
3.1%
|
4.6%
|
Total
operating profit margin was lower in Q1 2024 primarily due to
unfavourable movements in contingent consideration liabilities
reflecting improved longer term HIV prospects and foreign currency
movement, partly offset by a fair value gain on the retained stake
in Haleon (Q1 2023 fair value loss).
Core
operating profit in the quarter benefitted from strong sales,
favourable product mix and the reversal of the legal provision
taken in Q1 2023 for the Zejula royalty dispute, following a
successful appeal. This was partly offset by increased investment
in R&D and growth assets, and lower royalty income. The adverse
impact of lower sales of COVID-19 solutions was eight percentage
points of Core operating profit growth, with minimal impact on Core
operating profit margin.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Net
finance costs
|
Total
|
134
|
(23%)
|
(22%)
|
|
|
Core
|
132
|
(22%)
|
(22%)
|
The
decrease in net finance costs in Q1 2024 was mainly driven by the
net cost of certain bond buybacks completed in Q1 2023 and higher
interest income on cash.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Taxation
|
Total
|
274
|
(1%)
|
13%
|
|
|
Tax rate %
|
20.2%
|
|
|
|
|
Core
|
404
|
33%
|
46%
|
|
|
Tax rate %
|
17.5%
|
|
|
The
effective tax rate on Core profits is broadly in line with
expectations for the year and includes the impact of the
OECD’s BEPS Pillar Two model framework which came into
effect from 1 January 2024. Issues related to taxation are
described in Note 14, ‘Taxation’ in the Annual Report
2023. The Group continues to believe it has made adequate provision
for the liabilities likely to arise from periods that are open and
not yet agreed by relevant tax authorities. The ultimate liability
for such matters may vary from the amounts provided and is
dependent upon the outcome of agreements with relevant tax
authorities.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m
|
AER
|
CER
|
|
Non-controlling
interests
("NCIs")
|
Total
|
35
|
(75%)
|
(66%)
|
|
Core
|
154
|
27%
|
38%
|
|
The
decrease in Total profit allocated to NCIs in the quarter was
primarily driven by lower ViiV Healthcare profits (including the
remeasurement loss on the contingent consideration liability) with
an allocation of £28 million (Q1 2023: £140 million),
partly offset by higher net profits in some of the Group's other
entities.
The
increase in Core profit from operations allocated to NCIs in Q1
2024 primarily reflected higher profit allocations from ViiV
Healthcare of £147 million (Q1 2023: £120 million), as
well as higher net profits in some of the Group’s other
entities with NCIs.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£p
|
AER
|
CER
|
|
Earnings
per share
|
Total
|
25.7p
|
(30%)
|
(19%)
|
|
Core
|
43.1p
|
16%
|
28%
|
|
The
increase in the Core EPS in the quarter reflected the growth in
Core operating profit as well as lower finance costs, partly offset
by higher non-controlling interests and a higher effective taxation
rate. Lower sales of COVID-19 solutions reduced Core EPS by nine
percentage points.
The
decrease in the Q1 2024 Total EPS primarily reflected higher
charges related to the remeasurement of contingent consideration
liabilities reflecting improved longer term HIV prospects and
foreign currency movement partly offset by a fair value gain on the
retained stake in Haleon (compared to a fair value loss in Q1 2023)
and a favourable benefit from lower non-controlling
interests.
Currency impact on results
The
results for Q1 2024 are based on average exchange rates,
principally £1/$1.27, £1/€1.16 and £1/Yen 187.
The period-end exchange rates were £1/$1.26,
£1/€1.17 and £1/Yen 191. Comparative exchange rates
are given on page 34.
|
|
|
|
|
|
|
|
|
Q1 2024
|
||
|
|
|
£m/£p
|
AER
|
CER
|
|
Turnover
|
|
7,363
|
6%
|
10%
|
|
Earnings
per share
|
Total
|
25.7p
|
(30%)
|
(19%)
|
|
Core
|
43.1p
|
16%
|
28%
|
|
In Q1
2024, the adverse currency impact primarily reflected the
strengthening of Sterling against the US Dollar, Euro and Yen, as
well as the weakening of emerging market currencies against
Sterling. Exchange gains or losses on the settlement of
intercompany transactions had an adverse two percentage point
impact on Core EPS.
|
Cash
generation
|
|
|
|
|
|
|
|
|
|
|
Cash flow
|
|||
|
|
Q1 2024
£m
|
|
Q1 2023
£m
|
|
|
|
|
|
|
Cash
generated from operations (£m)
|
1,126
|
|
287
|
|
|
|
|
|
|
Net
cash generated from operating activities (£m)
|
958
|
|
53
|
|
|
|
|
|
|
Free
cash inflow/(outflow)* (£m)
|
289
|
|
(689)
|
|
Free
cash flow growth (%)
|
>100%
|
|
>(100)%
|
|
Free
cash flow conversion* (%)
|
28%
|
|
3%
|
|
Total
net debt** (£m)
|
14,961
|
|
17,950
|
|
*
|
Free cash flow and free cash
flow conversion are defined on page 47. Free cash flow is analysed
on page 37.
|
|
**
|
Net debt is analysed on page
37.
|
Q1 2024
Cash
generated from operations for the quarter was £1,126 million
(Q1 2023: £287 million). The increase primarily reflected
higher operating profit and higher receivables' collections, driven
by the timing of sales and collections particularly for
Arexvy, partly offset by
timing of returns and rebates.
Total
contingent consideration cash payments in the quarter were
£309 million (Q1 2023: £291 million), including cash
payments made to Shionogi & Co. Ltd (Shionogi) of
£300 million (Q1 2023: £287 million). £306
million (Q1 2023: £290 million) of these were recognised
in cash flows from operating activities.
Free
cash inflow was £289 million for the quarter (Q1 2023:
£689 million outflow). In addition to the increase in
cash generated from operations the increase in free cash flow in
the quarter was primarily driven by lower tax payments, lower net
interest paid and lower dividends paid to non-controlling
interests. This was partly offset by increased capital
expenditure.
Total Net debt
At
31 March 2024, net debt was £14,961 million, compared with
£15,040 million at 31 December 2023, comprising gross debt of
£17,772 million and cash and liquid investments of £2,811
million. See net debt information on page 36.
Net
debt decreased by £79 million primarily due to £289
million free cash inflow and £1,055 million proceeds from the
disposal of investments, including the partial sale of the retained
stake in Haleon. This was partly offset by the net acquisition cost
of Aiolos Bio, Inc. (Aiolos) for £719 million and dividends
paid to shareholders of £568 million.
At 31
March 2024, GSK had short-term borrowings (including overdrafts and
lease liabilities) repayable within 12 months of £2,616
million with loans of £1,431 million repayable in the
subsequent year.
|
|
|
|
Contents
|
Page
|
|
Q1 2024
pipeline highlights
|
14
|
|
ESG
|
16
|
|
Total
and Core results
|
18
|
|
Income
statement
|
23
|
|
Statement
of comprehensive income
|
24
|
|
Balance
sheet
|
25
|
|
Statement
of changes in equity
|
26
|
|
Cash
flow statement - three months ended 31 March 2024
|
27
|
|
Sales
tables - three months ended 31 March 2024
|
28
|
|
Segment
information
|
31
|
|
Legal
matters
|
32
|
|
Returns
to shareholders
|
33
|
|
Additional
information
|
34
|
|
Net
debt information
|
36
|
|
Related
party transactions
|
37
|
|
R&D
commentary
|
38
|
|
Reporting
definitions
|
47
|
|
Guidance,
assumptions and cautionary statements
|
49
|
|
Independent
Auditor's review report to GSK plc
|
50
|
|
|
|
|
Contacts
|
|
|
|
|
|
GSK plc
(LSE/NYSE:GSK) is a global biopharma company with a purpose to
unite science, technology, and talent to get ahead of disease
together. Find out more at
www.gsk.com.
|
|
|
|
|
|
|
|
|
GSK enquiries:
|
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
|
|
Investor
Relations
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
|
Joshua
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
|
Jeff
McLaughlin
|
+1 215
589 3774
|
(Philadelphia)
|
|
|
|
|
|
|
|
|
Registered in England & Wales:
No.
3888792
|
||||
|
|
||||
|
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
|
||||
|
|
|
|||
|
Q1 2024 pipeline highlights (since
31 January 2024)
|
|
|||
|
|
|
|
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory submissions or acceptances
|
Arexvy
|
RSV,
adults aged 50-59 years
|
Regulatory
acceptance (US)
|
|
MenABCWY
(gen 1) vaccine candidate
|
Meningococcal
ABCWY
|
Regulatory
acceptance (US)
|
|
|
Shingrix
|
Shingles,
adults aged 18+ years
|
Regulatory
acceptance (CN)
|
|
|
Jemperli
|
RUBY
part 1 (OS overall population, 1L endometrial cancer)
|
Regulatory
acceptance (US)
|
|
|
Phase III data readouts or other significant events
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Positive
phase III data readout
|
|
Blenrep
|
DREAMM-8
(2L + multiple myeloma)
|
Positive
phase III data readout
|
|
|
cabotegravir
|
LATITUDE
(HIV long-acting injectable)
|
Positive
phase III data readout
|
|
|
Jemperli
|
RUBY
Part 1 (OS) and Part 2 (PFS) (1L endometrial cancer)
|
Additional
positive phase III data readout
|
|
|
|
|
|
|
|||
|
Anticipated news flow
|
|||||||
|
|
|
|
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H1
2024
|
Arexvy
|
RSV,
older adults aged 50-59 years
|
Regulatory
decision (US)
|
|
momelotinib
|
MOMENTUM
(myelofibrosis with anaemia)
|
Regulatory
decision (JP)
|
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Phase
III data readout
|
|
|
H2
2024
|
Arexvy
|
RSV,
older adults aged 50-59 years
|
Regulatory
decision (EU, JP)
|
|
gepotidacin
|
EAGLE-2/3
(uncomplicated urinary tract infection)
|
Regulatory
submission (US)
|
|
|
MenABCWY
(gen 1)
vaccine
candidate
|
Meningococcal
ABCWY
|
Regulatory
submission (EU)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Phase
III data readout
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
submission (US)
|
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
submission (US)
|
|
|
Nucala
|
Chronic
rhinosinusitis with nasal polyps
|
Regulatory
decision (JP)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Phase
III data readout
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
submission (US)
|
|
|
Blenrep
|
DREAM-7/8
(2L + multiple myeloma)
|
Regulatory
submission
(US,
EU, JP)
|
|
|
Blenrep
|
DREAMM-7
(2L + multiple myeloma)
|
Regulatory
submission (CN)
|
|
|
Jemperli
|
RUBY
part 1 (OS overall population, 1L endometrial cancer)
|
Regulatory
decision (US)
|
|
|
Jemperli
|
RUBY
part 1 (OS overall population, 1L endometrial cancer)
|
Regulatory
submission (EU)
|
|
|
Zejula
|
FIRST
(1L maintenance ovarian cancer)
|
Phase
III data readout
|
|
|
Zejula
|
ZEAL
(1L maintenance non-small cell lung cancer)
|
Phase
III data readout
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Phase
III data readout
|
|
Anticipated news flow continued
|
|
|||
|
|
|
|
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
2025
|
gepotidacin
|
EAGLE-2/3
(uncomplicated urinary tract infection)
|
Regulatory
decision (US)
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
submission (US)
|
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
decision (US)
|
|
|
geopotidacin
|
EAGLE-J
(uncomplicated urinary tract infection)
|
Regulatory
submission (JP)
|
|
|
MenABCWY
(gen 1) vaccine candidate
|
Meningococcal
ABCWY
|
Regulatory
decision (US)
|
|
|
Shingrix
|
Shingles,
adults aged 18+ years
|
Regulatory
decision (CN)
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Phase
III data readout
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
submission (US)
|
|
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Phase
III data readout
|
|
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Regulatory
submission
(US,
EU)
|
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
decision (US, JP)
|
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
submission
(EU,
CN, JP)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
decision (US, JP)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
submission
(EU,
CN, JP)
|
|
|
depemokimab
|
OCEAN
(eosinophilic granulomatosis with polyangiitis)
|
Phase
III data readout
|
|
|
Nucala
|
Chronic
rhinosinusitis with nasal polyps
|
Regulatory
decision (CN)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
decision (US)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
submission
(CN,
EU)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision
(US,
EU, JP)
|
|
|
Blenrep
|
DREAMM-8
(2L+ multiple myeloma)
|
Regulatory
submission (CN)
|
|
|
cobolimab
|
COSTAR
(non-small cell lung cancer)
|
Phase
III data readout
|
|
|
cobolimab
|
COSTAR,
(2L non-small cell lung cancer)
|
Regulatory
submission
(US,
EU)
|
|
|
Jemperli
|
RUBY
part 1 (OS overall population, 1L endometrial cancer)
|
Regulatory
decision (EU)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
submission
(US,
EU, CN, JP)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision (US)
|
|
Refer
to pages 38 to 46 for further details on several key medicines and
vaccines in development by therapy area.
|
Trust: progress on our six priority
areas for responsible business
Building
Trust by operating responsibly is integral to GSK’s strategy
and culture. This will support growth and returns to shareholders,
reduce risk, and help GSK’s people thrive while delivering
sustainable health impact at scale. The company has identified six
Environmental, Social, and Governance (ESG) focus areas that
address what is most material to GSK’s business and the
issues that matter the most to its stakeholders. Highlights below
include activity since Q4 2023 results. For more details on annual
updates, please see GSK's ESG
Performance
Report
2023. (1)
Access
Commitment:
to make GSK’s vaccines and medicines available at value-based
prices that are sustainable for the business and implement access
strategies that increase the use of GSK’s vaccines and
medicines to treat and protect underserved people.
Progress
since Q4 2023:
|
|
|
|
●
|
GSK
announced a cap of $35 per month on eligible U.S. patient
out-of-pocket costs for its entire portfolio of asthma and COPD
inhalers. This announcement builds on GSK’s decades-long
commitment to making products accessible to those who need them.
More information can be found here. (2)
|
|
●
|
GSK
announced additional funding and new data and resources under the
COiMMUNITY Initiative to help achieve higher adult vaccination
rates and health equity in the US and address ongoing barriers to
adult immunisation. In 2024, GSK is giving up to $2 million in
COiMMUNITY Initiative grants. More information can be found
here. (3)
|
|
●
|
Performance
metrics related to access are updated annually with related details
in GSK’s ESG Performance Report 2023 on page 10.
|
Global health and health security
Commitment:
develop novel products and technologies to treat and prevent
priority diseases, including pandemic threats.
Progress
since Q4 2023:
|
|
|
|
●
|
GSK
announced positive headline results from EAGLE-1 phase III trial
for gepotidacin in uncomplicated urogenital gonorrhoea. Neisseria
gonorrhoeae, the bacteria causing gonorrhoea, is recognised by the
World Health Organisation as a priority pathogen, for which
resistance to existing treatments is rising. More information can
be found here. (4)
|
|
●
|
In
March, the GSK-developed tuberculosis (TB) vaccine candidate
M72/AS01E entered phase III trials, sponsored by Wellcome and the
Bill & Melinda Gates Medical Research Institute. This is the
first potential new TB vaccine which meets the WHO target product
profile in over 100 years. More information on GSK’s TB and
Global health efforts can be found here. (5)
|
|
●
|
Performance
metrics related to global health and health security are updated
annually with related details in GSK’s ESG Performance Report
2023 on page 15.
|
Environment
Commitment:
committed to a net zero, nature-positive, healthier planet with
ambitious goals set for 2030 and 2045.
Progress
since Q4 2023:
|
|
|
|
●
|
In
February, the global environmental non-profit CDP published its
annual scoring of corporate environmental performance. CDP sets
high and constantly evolving standards for environmental leadership
to support companies to improve their level of ambition and action
on climate and nature. This year’s results, which are based
on 2022 performance, reflect a year-over-year improvement for GSK
for Water Security score (A- from B) and a continued high A- score
for Climate Change. GSK also scored well in two Forest commodities
receiving a B for paper and B for palm oil.
|
|
●
|
In
February, GSK announced a virtual power purchase agreement to
source renewable electricity through two new solar projects in
Spain to facilitate 50% of its European sites' electricity demand
for 12 years, from mid-2026.
|
|
●
|
Whilst
GSK is focused on emissions reductions to meet its carbon targets,
at the same time, it is investing in high quality nature protection
and restoration projects that support GSK’s net-zero and
nature positive goals, and deliver co-benefits to human health. In
March, GSK disclosed it has invested in Climate Asset
Management’s Nature Based Carbon Fund, which aims to invest
in nature projects in developing economies, to provide
long-lasting, verified, positive impact at scale for the climate,
biodiversity and local communities. This is a long-term investment
over the next 15 years, which aims to secure approximately a
quarter of credits needed in 2030, to meet GSK’s commitment
to invest in nature-based solutions for 20% of its 2020
footprint.
|
|
●
|
Performance
metrics related to environment are updated annually with related
details in GSK’s ESG Performance Report 2023 on page
18.
|
Diversity, equity and inclusion
Commitment:
create a diverse, equitable and inclusive workplace; enhance
recruitment of diverse patient populations in GSK clinical trials;
and support diverse communities.
Progress
since Q4 2023:
|
|
|
|
●
|
Performance
metrics related to diversity, equity and inclusion are updated
annually with related details in GSK’s ESG Performance Report
2023 on page 26.
|
Ethical standards
Commitment:
promote ethical behaviour across GSK’s business by supporting
its employees to do the right thing and working with suppliers that
share GSK’s standards and operate responsibly.
|
|
|
|
●
|
Performance
metrics related to ethical standards are updated annually with
related details in GSK’s ESG Performance Report 2023 on page
30.
|
Product governance
Commitment:
maintain robust quality and safety processes and responsibly use
data and new technologies.
|
|
|
|
●
|
Performance
metrics related to product governance are updated annually with
related details in GSK’s ESG Performance Report 2023 on page
35.
|
ESG rating performance
Detailed
below is how GSK performs in key ESG ratings.
|
|
|
|
|
|
External benchmark
|
Current
score/ranking
|
Previous
score/ranking
|
Comments
|
|
S&P
Global’s Corporate Sustainability Assessment
|
84
|
86
|
1st in
the pharmaceutical industry group; Assessment conducted annually,
current score updated Nov 2023
|
|
Access
to Medicines Index
|
4.06
|
4.23
|
Led the
bi-annual index since its inception in 2008; Updated bi-annually,
current results from Nov 2022
|
|
Antimicrobial
resistance benchmark
|
84%
|
86%
|
Led the
bi-annual benchmark since its inception in 2018; Current ranking
updated Nov 2021
|
|
CDP
Climate Change
|
A-
|
A-
|
Updated
annually, current scores updated Feb 2024 (for supplier engagement,
March 2023)
|
|
CDP
Water Security
|
A-
|
B
|
|
|
CDP
Forests (palm oil)
|
B
|
A-
|
|
|
CDP
Forests (timber)
|
B
|
B
|
|
|
CDP
supplier engagement rating
|
Leader
|
Leader
|
|
|
Sustainalytics
|
16.7
|
18.6
|
1st
percentile in pharma subindustry group; Lower score represents
lower risk. Current ranking updated Sept 2023
|
|
MSCI
|
AA
|
AA
|
Last
rating action date: Sept 2023
|
|
Moody’s
ESG solutions
|
62
|
61
|
Current
score updated Aug 2023
|
|
ISS
Corporate Rating
|
B+
|
B+
|
Current
score updated June 2023
|
|
FTSE4Good
|
Member
|
Member
|
Member
since 2004, latest review in June 2023
|
|
ShareAction’s
Workforce Disclosure Initiative
|
79%
|
77%
|
Current
score updated Jan 2024
|
Footnotes:
|
(1)
|
https://www.gsk.com/media/11009/esg-performance-report-2023.pdf
|
|
(2)
|
https://us.gsk.com/en-us/media/press-releases/gsk-announces-cap-of-35-per-month-on-us-patient-out-of-pocket-costs-for-its-entire-portfolio-of-asthma-and-copd-inhalers/
|
|
(3)
|
https://us.gsk.com/en-us/media/press-releases/gsk-doubles-coimmunity-grant-funding-launches-patient-resources-as-adult-vaccination-rates-begin-to-show-promising-rise/
|
|
(4)
|
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-eagle-1-phase-iii-trial-for-gepotidacin-in-uncomplicated-urogenital-gonorrhoea-gc/
|
|
(5)
|
https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/
|
Total and Core
results
Total
reported results represent the Group’s overall
performance.
GSK has
made one update to its reporting framework in Q1 2024 which is to
change the description of Adjusted results to Core results to align
with European peers in the pharmaceutical industry but with no
change to the basis or figures. There is no change to Total Results
or the definition of Adjusting items.
GSK
uses a number of non-IFRS measures to report the performance of its
business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for, or superior
to, information presented in accordance with IFRS. Core results are
defined below and other non-IFRS measures are defined on page
47.
GSK
believes that Core results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Core
results exclude the following items in relation to our operations
from Total results, together with the tax effects of all of these
items:
|
|
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses from operations are retained within both Total
and Core results.
As Core
results include the benefits of Major restructuring programmes but
exclude significant costs (such as significant legal, major
restructuring and transaction items) they should not be regarded as
a complete picture of the Group’s financial performance,
which is presented in Total results. The exclusion of other
Adjusting items may result in Core earnings being materially higher
or lower than Total earnings. In particular, when significant
impairments, restructuring charges and legal costs are excluded,
Core earnings will be higher than Total earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Core results, providing further information on
the key Adjusting items, are set out on pages 20 and
21.
GSK
provides earnings guidance to the investor community on the basis
of Core results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 84% of the Total
earnings and 83% of the Core earnings of ViiV Healthcare for
2023.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent remeasurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in the three months
ended 31 March 2024 were £300 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 84 and 85 of the Annual Report
2023.
Adjusting items
The
reconciliations between Total results and Core results for Q1 2024
and Q1 2023 are set out below.
|
Three
months ended 31 March 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
7,363
|
|
|
|
|
|
|
|
|
|
|
|
7,363
|
|
Cost of
sales
|
(1,970)
|
|
182
|
|
|
|
33
|
|
19
|
|
3
|
|
(1,733)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,393
|
|
182
|
|
|
|
33
|
|
19
|
|
3
|
|
5,630
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,087)
|
|
|
|
|
|
17
|
|
|
|
91
|
|
(1,979)
|
|
Research
and development
|
(1,434)
|
|
14
|
|
54
|
|
7
|
|
|
|
|
|
(1,359)
|
|
Royalty
income
|
151
|
|
|
|
|
|
|
|
|
|
|
|
151
|
|
Other
operating income/(expense)
|
(533)
|
|
|
|
|
|
|
|
685
|
|
(152)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,490
|
|
196
|
|
54
|
|
57
|
|
704
|
|
(58)
|
|
2,443
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(134)
|
|
|
|
|
|
|
|
|
|
2
|
|
(132)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates
and joint ventures
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,355
|
|
196
|
|
54
|
|
57
|
|
704
|
|
(56)
|
|
2,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(274)
|
|
(41)
|
|
(14)
|
|
(13)
|
|
(76)
|
|
14
|
|
(404)
|
|
Tax rate %
|
20.2%
|
|
|
|
|
|
|
|
|
|
|
|
17.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,081
|
|
155
|
|
40
|
|
44
|
|
628
|
|
(42)
|
|
1,906
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling
interests
|
35
|
|
|
|
|
|
|
|
119
|
|
|
|
154
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to shareholders
|
1,046
|
|
155
|
|
40
|
|
44
|
|
509
|
|
(42)
|
|
1,752
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,081
|
|
155
|
|
40
|
|
44
|
|
628
|
|
(42)
|
|
1,906
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
25.7p
|
|
3.8p
|
|
1.0p
|
|
1.1p
|
|
12.5p
|
|
(1.0p)
|
|
43.1p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,069
|
|
|
|
|
|
|
|
|
|
|
|
4,069
|
|
Three
months ended 31 March 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
6,951
|
|
|
|
|
|
|
|
|
|
|
|
6,951
|
|
Cost of
sales
|
(1,943)
|
|
151
|
|
|
|
35
|
|
|
|
5
|
|
(1,752)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,008
|
|
151
|
|
|
|
35
|
|
|
|
5
|
|
5,199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,143)
|
|
|
|
|
|
69
|
|
|
|
9
|
|
(2,065)
|
|
Research
and development
|
(1,260)
|
|
18
|
|
16
|
|
4
|
|
|
|
|
|
(1,222)
|
|
Royalty
income
|
180
|
|
|
|
|
|
|
|
|
|
|
|
180
|
|
Other
operating income/(expense)
|
297
|
|
|
|
|
|
|
|
(271)
|
|
(26)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,082
|
|
169
|
|
16
|
|
108
|
|
(271)
|
|
(12)
|
|
2,092
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(174)
|
|
|
|
|
|
|
|
|
|
4
|
|
(170)
|
|
Share
of after tax profit/(loss) of associates
and joint ventures
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
|
Profit/(loss)
on disposal of interest in associates
|
1
|
|
|
|
|
|
|
|
|
|
(1)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,907
|
|
169
|
|
16
|
|
108
|
|
(271)
|
|
(9)
|
|
1,920
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(276)
|
|
(36)
|
|
(4)
|
|
(22)
|
|
15
|
|
20
|
|
(303)
|
|
Tax rate %
|
14.5%
|
|
|
|
|
|
|
|
|
|
|
|
15.8%
|
|
Profit after taxation
|
1,631
|
|
133
|
|
12
|
|
86
|
|
(256)
|
|
11
|
|
1,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling
interests
|
141
|
|
|
|
|
|
|
|
(20)
|
|
|
|
121
|
|
Profit attributable to shareholders
|
1,490
|
|
133
|
|
12
|
|
86
|
|
(236)
|
|
11
|
|
1,496
|
|
|
1,631
|
|
133
|
|
12
|
|
86
|
|
(256)
|
|
11
|
|
1,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
36.8p
|
|
3.3p
|
|
0.3p
|
|
2.1p
|
|
(5.8p)
|
|
0.3p
|
|
37.0p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,044
|
|
|
|
|
|
|
|
|
|
|
|
4,044
|
Major restructuring and integration
Total
Major restructuring charges incurred in Q1 2024 were £57
million (Q1 2023: £108 million), analysed as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2024
|
|
Q1
2023
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
Preparation restructuring
programme
|
28
|
|
8
|
|
36
|
|
37
|
|
47
|
|
84
|
|
Significant
acquisitions
|
19
|
|
–
|
|
19
|
|
21
|
|
1
|
|
22
|
|
Legacy
programmes
|
2
|
|
–
|
|
2
|
|
–
|
|
2
|
|
2
|
|
|
49
|
|
8
|
|
57
|
|
58
|
|
50
|
|
108
|
The
Separation Preparation programme incurred cash charges of £28
million primarily from restructuring in Global Supply Chain as well
as some commercial and administrative functions. The non-cash
charges of £8 million primarily reflected the write down of
assets in manufacturing locations.
Costs
of significant acquisitions relate to integration costs of Sierra
Oncology Inc. (Sierra) and Affinivax Inc. (Affinivax) which were
acquired in Q3 2022, BELLUS Health Inc. (Bellus) acquired in Q2
2023 and Aiolos acquired in Q1 2024.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £704 million (Q1 2023:
£271 million credit), the majority of which related to
charges/credits for the remeasurement of contingent consideration
liabilities, the liabilities for the Pfizer put option, and Pfizer
and Shionogi preferential dividends in ViiV
Healthcare.
|
|
|
|
|
|
Charge/(credit)
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including Shionogi preferential dividends)
|
586
|
|
(64)
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
66
|
|
(105)
|
|
Contingent
consideration on former Novartis Vaccines business
|
28
|
|
(69)
|
|
Contingent
consideration on acquisition of Affinivax
|
5
|
|
(33)
|
|
Other
adjustments
|
19
|
|
–
|
|
|
|
|
|
|
Total
transaction-related charges
|
704
|
|
(271)
|
The
£586 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi by £479 million from updated sales forecasts and
exchange rates, and the unwind of the discount for £107
million. The £66 million charge relating to the ViiV
Healthcare put option and Pfizer preferential dividends represented
an increase in the valuation of the put option primarily as a
result of updated sales forecasts.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. An explanation of the accounting for the
non-controlling interests in ViiV Healthcare is set out on page
19.
The
£28 million charge relating to the contingent consideration on
the former Novartis Vaccines business primarily relates to changes
to future sales forecasts.
The
£5 million charge relating to the contingent consideration on
the acquisition of Affinivax primarily relates to the unwind of the
discount.
Divestments, significant legal charges, and other
items
Divestments,
significant legal charges, and other items primarily included fair
value gains on investments, including a £57 million fair value
gain on the investment in Haleon and other net income of £95
million. Legal charges provide for all significant legal matters
and are not broken out separately by litigation or investigation.
Significant legal charges in the quarter primarily reflected
prospective legal costs for the defence of the litigation relating
to Zantac.
|
|
||||
|
Financial
information
|
||||
|
Income
statements
|
|
|
|
|
|
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
|
|
|
|
|
TURNOVER
|
7,363
|
|
6,951
|
|
|
|
|
|
|
Cost of
sales
|
(1,970)
|
|
(1,943)
|
|
Gross
profit
|
5,393
|
|
5,008
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,087)
|
|
(2,143)
|
|
Research
and development
|
(1,434)
|
|
(1,260)
|
|
Royalty
income
|
151
|
|
180
|
|
Other
operating income/(expense)
|
(533)
|
|
297
|
|
|
|
|
|
|
OPERATING PROFIT
|
1,490
|
|
2,082
|
|
|
|
|
|
|
Finance
income
|
32
|
|
29
|
|
Finance
expense
|
(166)
|
|
(203)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
(2)
|
|
Profit/(loss)
on disposal of interests in associates and joint
ventures
|
–
|
|
1
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
1,355
|
|
1,907
|
|
|
|
|
|
|
Taxation
|
(274)
|
|
(276)
|
|
Tax rate %
|
20.2%
|
|
14.5%
|
|
|
|
|
|
|
PROFIT AFTER TAXATION
|
1,081
|
|
1,631
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
35
|
|
141
|
|
Profit
attributable to shareholders
|
1,046
|
|
1,490
|
|
|
1,081
|
|
1,631
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
25.7p
|
|
36.8p
|
|
|
|
|
|
|
Diluted
earnings per share
|
25.4p
|
|
36.5p
|
|
|
|
|
|
|
|
||||
|
Statement of comprehensive
income
|
|
|
|
|
|
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
|
|
|
|
|
Total
profit for the period
|
1,081
|
|
1,631
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
(190)
|
|
87
|
|
Reclassification
of exchange movements on liquidation or disposal of
overseas subsidiaries and associates
|
–
|
|
(3)
|
|
Reclassification
of cash flow hedges to income statement
|
2
|
|
1
|
|
|
|
|
|
|
|
(188)
|
|
85
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
3
|
|
(14)
|
|
Fair
value movements on equity investments
|
78
|
|
(168)
|
|
Tax on
fair value movements on equity investments
|
(15)
|
|
22
|
|
Fair
value movements on cash flow hedges
|
1
|
|
–
|
|
Remeasurement
gains/(losses) on defined benefit plans
|
46
|
|
350
|
|
Tax on
remeasurement losses/(gains) on defined benefit plans
|
(10)
|
|
(87)
|
|
|
|
|
|
|
|
103
|
|
103
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the period
|
(85)
|
|
188
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
996
|
|
1,819
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
Shareholders
|
958
|
|
1,692
|
|
Non-controlling
interests
|
38
|
|
127
|
|
|
|
|
|
|
|
996
|
|
1,819
|
|
|
|||||
|
Balance
sheet
|
|
|
|
|
|
|
|
31 March 2024
£m
|
|
31
December 2023
£m
|
|
ASSETS
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
8,952
|
|
9,020
|
|
Right
of use assets
|
915
|
|
937
|
|
Goodwill
|
6,978
|
|
6,811
|
|
Other
intangible assets
|
15,667
|
|
14,768
|
|
Investments
in associates and joint ventures
|
46
|
|
55
|
|
Other
investments
|
1,231
|
|
1,137
|
|
Deferred
tax assets
|
5,863
|
|
6,049
|
|
Other
non-current assets
|
1,654
|
|
1,584
|
|
|
|
|
|
|
Total non-current assets
|
41,306
|
|
40,361
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
5,702
|
|
5,498
|
|
Current
tax recoverable
|
460
|
|
373
|
|
Trade
and other receivables
|
6,831
|
|
7,385
|
|
Derivative
financial instruments
|
57
|
|
130
|
|
Current
equity investments
|
1,284
|
|
2,204
|
|
Liquid
investments
|
21
|
|
42
|
|
Cash
and cash equivalents
|
2,790
|
|
2,936
|
|
Assets
held for sale
|
60
|
|
76
|
|
|
|
|
|
|
Total current assets
|
17,205
|
|
18,644
|
|
|
|
|
|
|
TOTAL ASSETS
|
58,511
|
|
59,005
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current liabilities
|
|
|
|
|
Short-term
borrowings
|
(2,616)
|
|
(2,813)
|
|
Contingent
consideration liabilities
|
(1,094)
|
|
(1,053)
|
|
Trade
and other payables
|
(14,621)
|
|
(15,844)
|
|
Derivative
financial instruments
|
(69)
|
|
(114)
|
|
Current
tax payable
|
(720)
|
|
(500)
|
|
Short-term
provisions
|
(726)
|
|
(744)
|
|
|
|
|
|
|
Total current liabilities
|
(19,846)
|
|
(21,068)
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Long-term
borrowings
|
(15,156)
|
|
(15,205)
|
|
Corporation
tax payable
|
(76)
|
|
(75)
|
|
Deferred
tax liabilities
|
(288)
|
|
(311)
|
|
Pensions
and other post-employment benefits
|
(2,306)
|
|
(2,340)
|
|
Other
provisions
|
(510)
|
|
(495)
|
|
Contingent
consideration liabilities
|
(5,981)
|
|
(5,609)
|
|
Other
non-current liabilities
|
(1,119)
|
|
(1,107)
|
|
|
|
|
|
|
Total non-current liabilities
|
(25,436)
|
|
(25,142)
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(45,282)
|
|
(46,210)
|
|
|
|
|
|
|
NET ASSETS
|
13,229
|
|
12,795
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
Share
capital
|
1,348
|
|
1,348
|
|
Share
premium account
|
3,471
|
|
3,451
|
|
Retained
earnings
|
7,935
|
|
7,239
|
|
Other
reserves
|
1,086
|
|
1,309
|
|
|
|
|
|
|
Shareholders’ equity
|
13,840
|
|
13,347
|
|
|
|
|
|
|
Non-controlling
interests
|
(611)
|
|
(552)
|
|
|
|
|
|
|
TOTAL EQUITY
|
13,229
|
|
12,795
|
|
|
|
|
|||
|
Statement of changes in
equity
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2024
|
1,348
|
|
3,451
|
|
7,239
|
|
1,309
|
|
13,347
|
|
(552)
|
|
12,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,046
|
|
|
|
1,046
|
|
35
|
|
1,081
|
|
Other comprehensive
income/(expense) for the period
|
|
|
|
|
(151)
|
|
63
|
|
(88)
|
|
3
|
|
(85)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for the period
|
|
|
|
|
895
|
|
63
|
|
958
|
|
38
|
|
996
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(97)
|
|
(97)
|
|
Dividends
to shareholders
|
|
|
|
|
(568)
|
|
|
|
(568)
|
|
|
|
(568)
|
|
Realised
after tax losses on disposal
or liquidation of equity investments
|
|
|
|
|
(47)
|
|
47
|
|
|
|
|
|
–
|
|
Share
of associates and joint
ventures realised profit/(loss) on
disposal of equity investments
|
|
|
|
|
15
|
|
(15)
|
|
|
|
|
|
–
|
|
Shares
issued
|
|
|
18
|
|
|
|
|
|
18
|
|
|
|
18
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
|
|
(141)
|
|
141
|
|
|
|
|
|
–
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
457
|
|
(459)
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
85
|
|
|
|
85
|
|
|
|
85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31 March 2024
|
1,348
|
|
3,471
|
|
7,935
|
|
1,086
|
|
13,840
|
|
(611)
|
|
13,229
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2023
|
1,347
|
|
3,440
|
|
4,363
|
|
1,448
|
|
10,598
|
|
(502)
|
|
10,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,490
|
|
–
|
|
1,490
|
|
141
|
|
1,631
|
|
|
Other comprehensive
income/(expense) for the period
|
|
|
|
|
336
|
|
(134)
|
|
202
|
|
(14)
|
|
188
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for the period
|
|
|
|
|
1,826
|
|
(134)
|
|
1,692
|
|
127
|
|
1,819
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(140)
|
|
(140)
|
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
7
|
|
7
|
|
|
Dividends
to shareholders
|
|
|
|
|
(555)
|
|
|
|
(555)
|
|
|
|
(555)
|
|
|
Realised
after tax losses on disposal
or liquidation of equity
investments
|
|
|
|
|
(13)
|
|
13
|
|
|
|
|
|
–
|
|
|
Share
of associates and joint
ventures realised profits on
disposal of equity
investments
|
|
|
|
|
2
|
|
(2)
|
|
|
|
|
|
–
|
|
|
Share
issued
|
1
|
|
7
|
|
|
|
|
|
8
|
|
|
|
8
|
|
|
Write-down
of shares held by ESOP Trusts
|
|
|
|
|
(48)
|
|
48
|
|
|
|
|
|
–
|
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
1
|
|
(3)
|
|
|
|
|
|
–
|
|
|
Share-based
incentive plans
|
|
|
|
|
79
|
|
|
|
79
|
|
|
|
79
|
|
|
Hedging
gain/(loss) after taxation
transferred to non-financial assets
|
|
|
|
|
|
|
(2)
|
|
(2)
|
|
|
|
(2)
|
|
|
At 31
March 2023
|
1,348
|
|
3,449
|
|
5,655
|
|
1,368
|
|
11,820
|
|
(508)
|
|
11,312
|
|
|
|
|
|||||||||||||
|
Cash
flow statement three months ended 31 March 2024
|
||||||||||||||
|
|
|
|
|
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
Profit after tax
|
1,081
|
|
1,631
|
|
Tax on
profits
|
274
|
|
276
|
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
1
|
|
2
|
|
(Profit)/loss
on disposal of interest in associates and joint
ventures
|
–
|
|
(1)
|
|
Net
finance expense
|
134
|
|
174
|
|
Depreciation,
amortisation and other adjusting items
|
549
|
|
640
|
|
Decrease/(increase)
in working capital
|
(311)
|
|
(840)
|
|
Contingent
consideration paid
|
(306)
|
|
(290)
|
|
Decrease
in other net liabilities (excluding contingent consideration
paid)
|
(296)
|
|
(1,305)
|
|
Cash generated from operations
|
1,126
|
|
287
|
|
Taxation
paid
|
(168)
|
|
(234)
|
|
Total net cash inflow/(outflow) from operating
activities
|
958
|
|
53
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
Purchase
of property, plant and equipment
|
(248)
|
|
(233)
|
|
Proceeds
from sale of property, plant and equipment
|
1
|
|
7
|
|
Purchase
of intangible assets
|
(315)
|
|
(296)
|
|
Proceeds
from sale of intangible assets
|
27
|
|
4
|
|
Purchase
of equity investments
|
(18)
|
|
(56)
|
|
Proceeds
from sale of equity investments
|
1,055
|
|
10
|
|
Purchase
of businesses, net of cash acquired
|
(719)
|
|
–
|
|
Contingent
consideration paid
|
(3)
|
|
(1)
|
|
Disposal
of businesses
|
(3)
|
|
(6)
|
|
Interest
received
|
37
|
|
29
|
|
Decrease/(Increase)
in liquid investments
|
22
|
|
–
|
|
Dividends
from joint ventures and associates
|
–
|
|
1
|
|
Dividend
and distributions from investments
|
15
|
|
132
|
|
Proceeds
from disposal of associates and Joint ventures
|
–
|
|
1
|
|
Total net cash inflow/(outflow) from investing
activities
|
(149)
|
|
(408)
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
Issue
of share capital
|
18
|
|
8
|
|
Repayment
of long-term loans
|
–
|
|
(144)
|
|
Net
increase/(repayment) of other short-term loans
|
(323)
|
|
552
|
|
Repayment
of lease liabilities
|
(57)
|
|
(47)
|
|
Interest
paid
|
(71)
|
|
(120)
|
|
Dividends
paid to shareholders
|
(568)
|
|
(555)
|
|
Shares
acquired by ESOP Trusts
|
–
|
|
(2)
|
|
Distribution
to non-controlling interests
|
(97)
|
|
(140)
|
|
Contributions
from non-controlling interests
|
–
|
|
7
|
|
Other
financing items
|
38
|
|
123
|
|
Total net cash inflow/(outflow) from financing
activities
|
(1,060)
|
|
(318)
|
|
Increase/(decrease) in cash and bank overdrafts in the
period
|
(251)
|
|
(673)
|
|
Cash
and bank overdrafts at beginning of the period
|
2,858
|
|
3,425
|
|
Exchange
adjustments
|
(19)
|
|
(31)
|
|
Increase/(decrease)
in cash and bank overdrafts
|
(251)
|
|
(673)
|
|
Cash and bank overdrafts at end of the period
|
2,588
|
|
2,721
|
|
Cash
and bank overdrafts at end of the period comprise:
|
|
|
|
|
Cash
and cash equivalents
|
2,790
|
|
2,890
|
|
Overdrafts
|
(202)
|
|
(169)
|
|
|
2,588
|
|
2,721
|
|
|
||||||||||||||||||||||||
|
Vaccines turnover – three months ended 31 March
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
Shingles
|
945
|
|
13
|
|
18
|
|
470
|
|
(7)
|
|
(4)
|
|
229
|
|
7
|
|
9
|
|
246
|
|
>100
|
|
>100
|
|
Shingrix
|
945
|
|
13
|
|
18
|
|
470
|
|
(7)
|
|
(4)
|
|
229
|
|
7
|
|
9
|
|
246
|
|
>100
|
|
>100
|
|
Meningitis
|
299
|
|
7
|
|
11
|
|
121
|
|
2
|
|
6
|
|
101
|
|
(12)
|
|
(10)
|
|
77
|
|
67
|
|
74
|
|
Bexsero
|
217
|
|
–
|
|
3
|
|
72
|
|
(3)
|
|
1
|
|
98
|
|
(11)
|
|
(8)
|
|
47
|
|
38
|
|
41
|
|
Menveo
|
80
|
|
36
|
|
41
|
|
49
|
|
9
|
|
13
|
|
2
|
|
(50)
|
|
(50)
|
|
29
|
|
>100
|
|
>100
|
|
Other
|
2
|
|
(33)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
1
|
|
–
|
|
–
|
|
1
|
|
(50)
|
|
–
|
|
RSV
|
182
|
|
–
|
|
–
|
|
154
|
|
–
|
|
–
|
|
1
|
|
–
|
|
–
|
|
27
|
|
–
|
|
–
|
|
Arexvy
|
182
|
|
–
|
|
–
|
|
154
|
|
–
|
|
–
|
|
1
|
|
–
|
|
–
|
|
27
|
|
–
|
|
–
|
|
Influenza
|
13
|
|
8
|
|
8
|
|
2
|
|
>100
|
|
>100
|
|
–
|
|
–
|
|
–
|
|
11
|
|
–
|
|
–
|
|
Fluarix, FluLaval
|
13
|
|
8
|
|
8
|
|
2
|
|
>100
|
|
>100
|
|
–
|
|
–
|
|
–
|
|
11
|
|
–
|
|
–
|
|
Established Vaccines
|
838
|
|
3
|
|
7
|
|
331
|
|
(6)
|
|
(3)
|
|
178
|
|
(8)
|
|
(6)
|
|
329
|
|
22
|
|
28
|
|
Infanrix, Pediarix
|
145
|
|
(18)
|
|
(15)
|
|
87
|
|
(19)
|
|
(16)
|
|
31
|
|
(6)
|
|
(6)
|
|
27
|
|
(25)
|
|
(22)
|
|
Boostrix
|
138
|
|
(1)
|
|
3
|
|
85
|
|
(8)
|
|
(3)
|
|
33
|
|
6
|
|
10
|
|
20
|
|
25
|
|
25
|
|
Hepatitis
|
175
|
|
3
|
|
6
|
|
91
|
|
(7)
|
|
(4)
|
|
51
|
|
11
|
|
13
|
|
33
|
|
27
|
|
35
|
|
Rotarix
|
154
|
|
12
|
|
17
|
|
57
|
|
21
|
|
26
|
|
29
|
|
(12)
|
|
(9)
|
|
68
|
|
17
|
|
24
|
|
Synflorix
|
45
|
|
(27)
|
|
(24)
|
|
–
|
|
–
|
|
–
|
|
2
|
|
(75)
|
|
(75)
|
|
43
|
|
(20)
|
|
(17)
|
|
Priorix, Priorix Tetra,
Varilrix
|
78
|
|
47
|
|
53
|
|
6
|
|
>100
|
|
>100
|
|
29
|
|
(12)
|
|
(9)
|
|
43
|
|
>100
|
|
>100
|
|
Cervarix
|
32
|
|
19
|
|
26
|
|
–
|
|
–
|
|
–
|
|
4
|
|
(56)
|
|
(56)
|
|
28
|
|
56
|
|
67
|
|
Other
|
71
|
|
45
|
|
47
|
|
5
|
|
(17)
|
|
(33)
|
|
(1)
|
|
>(100)
|
|
>(100)
|
|
67
|
|
56
|
|
63
|
|
Vaccines excluding
COVID-19 solutions
|
2,277
|
|
17
|
|
22
|
|
1,078
|
|
10
|
|
14
|
|
509
|
|
(2)
|
|
–
|
|
690
|
|
58
|
|
66
|
|
Pandemic vaccines
|
–
|
|
>(100)
|
|
>(100)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
–
|
|
–
|
|
Pandemic
adjuvant
|
–
|
|
>(100)
|
|
>(100)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
–
|
|
–
|
|
Vaccines
|
2,277
|
|
12
|
|
16
|
|
1,078
|
|
10
|
|
14
|
|
509
|
|
(18)
|
|
(17)
|
|
690
|
|
58
|
|
66
|
|
|
|
Specialty Medicines turnover – three months ended 31 March
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
HIV
|
1,613
|
|
10
|
|
14
|
|
1,031
|
|
12
|
|
17
|
|
364
|
|
5
|
|
7
|
|
218
|
|
6
|
|
15
|
|
Dolutegravir
products
|
1,304
|
|
2
|
|
6
|
|
772
|
|
2
|
|
5
|
|
324
|
|
2
|
|
3
|
|
208
|
|
5
|
|
14
|
|
Tivicay
|
354
|
|
(1)
|
|
4
|
|
186
|
|
1
|
|
4
|
|
64
|
|
(3)
|
|
(2)
|
|
104
|
|
(2)
|
|
8
|
|
Triumeq
|
310
|
|
(17)
|
|
(14)
|
|
211
|
|
(15)
|
|
(12)
|
|
59
|
|
(21)
|
|
(20)
|
|
40
|
|
(20)
|
|
(16)
|
|
Juluca
|
157
|
|
5
|
|
8
|
|
122
|
|
10
|
|
14
|
|
32
|
|
(9)
|
|
(6)
|
|
3
|
|
(25)
|
|
(25)
|
|
Dovato
|
483
|
|
22
|
|
27
|
|
253
|
|
18
|
|
22
|
|
169
|
|
18
|
|
20
|
|
61
|
|
61
|
|
74
|
|
Rukobia
|
33
|
|
32
|
|
36
|
|
31
|
|
35
|
|
39
|
|
2
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
Cabenuva
|
213
|
|
68
|
|
73
|
|
171
|
|
66
|
|
73
|
|
35
|
|
75
|
|
80
|
|
7
|
|
75
|
|
50
|
|
Apretude
|
54
|
|
>100
|
|
>100
|
|
54
|
|
>100
|
|
>100
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
Other
|
9
|
|
(40)
|
|
(27)
|
|
3
|
|
(57)
|
|
(43)
|
|
3
|
|
(40)
|
|
(40)
|
|
3
|
|
–
|
|
33
|
|
Respiratory/Immunology
and Other
|
635
|
|
6
|
|
11
|
|
378
|
|
(4)
|
|
–
|
|
132
|
|
22
|
|
25
|
|
125
|
|
25
|
|
37
|
|
Nucala
|
374
|
|
8
|
|
13
|
|
180
|
|
(5)
|
|
(2)
|
|
109
|
|
22
|
|
26
|
|
85
|
|
23
|
|
36
|
|
Benlysta
|
260
|
|
3
|
|
8
|
|
198
|
|
(3)
|
|
1
|
|
27
|
|
17
|
|
22
|
|
35
|
|
35
|
|
46
|
|
Other
|
1
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(4)
|
|
–
|
|
(25)
|
|
5
|
|
–
|
|
–
|
|
Oncology
|
273
|
|
>100
|
|
>100
|
|
186
|
|
>100
|
|
>100
|
|
75
|
|
4
|
|
6
|
|
12
|
|
33
|
|
33
|
|
Zejula
|
141
|
|
24
|
|
27
|
|
72
|
|
44
|
|
50
|
|
58
|
|
5
|
|
7
|
|
11
|
|
22
|
|
22
|
|
Blenrep
|
–
|
|
(100)
|
|
>(100)
|
|
(1)
|
|
–
|
|
–
|
|
1
|
|
(91)
|
|
(91)
|
|
–
|
|
–
|
|
–
|
|
Jemperli
|
80
|
|
>100
|
|
>100
|
|
65
|
|
>100
|
|
>100
|
|
14
|
|
>100
|
|
>100
|
|
1
|
|
–
|
|
100
|
|
Ojjaara
|
52
|
|
–
|
|
–
|
|
50
|
|
–
|
|
–
|
|
2
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
Other
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
Specialty Medicines
excluding COVID-19
solutions
|
2,521
|
|
14
|
|
19
|
|
1,595
|
|
17
|
|
21
|
|
571
|
|
9
|
|
11
|
|
355
|
|
13
|
|
23
|
|
Pandemic
|
1
|
|
(97)
|
|
(97)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
1
|
|
(97)
|
|
(97)
|
|
Xevudy
|
1
|
|
(97)
|
|
(97)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
1
|
|
(97)
|
|
(97)
|
|
Specialty Medicines
|
2,522
|
|
13
|
|
17
|
|
1,595
|
|
17
|
|
21
|
|
571
|
|
9
|
|
11
|
|
356
|
|
3
|
|
12
|
|
|
|
General Medicines turnover – three months ended 31 March
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
Respiratory
|
1,725
|
|
(2)
|
|
2
|
|
863
|
|
4
|
|
8
|
|
361
|
|
(3)
|
|
(1)
|
|
501
|
|
(11)
|
|
(4)
|
|
Anoro Ellipta
|
119
|
|
(1)
|
|
3
|
|
44
|
|
(14)
|
|
(10)
|
|
52
|
|
13
|
|
15
|
|
23
|
|
–
|
|
4
|
|
Flixotide/Flovent
|
139
|
|
(11)
|
|
(8)
|
|
95
|
|
(10)
|
|
(8)
|
|
18
|
|
(14)
|
|
(10)
|
|
26
|
|
(13)
|
|
(10)
|
|
Relvar/Breo Ellipta
|
270
|
|
(1)
|
|
4
|
|
99
|
|
(1)
|
|
2
|
|
98
|
|
–
|
|
2
|
|
73
|
|
(4)
|
|
8
|
|
Seretide/Advair
|
282
|
|
(17)
|
|
(13)
|
|
92
|
|
(23)
|
|
(21)
|
|
61
|
|
(14)
|
|
(13)
|
|
129
|
|
(13)
|
|
(6)
|
|
Trelegy Ellipta
|
591
|
|
27
|
|
33
|
|
425
|
|
30
|
|
35
|
|
75
|
|
12
|
|
13
|
|
91
|
|
28
|
|
41
|
|
Ventolin
|
168
|
|
(18)
|
|
(15)
|
|
86
|
|
(20)
|
|
(17)
|
|
25
|
|
(11)
|
|
(7)
|
|
57
|
|
(17)
|
|
(14)
|
|
Other
Respiratory
|
156
|
|
(25)
|
|
(20)
|
|
22
|
|
10
|
|
20
|
|
32
|
|
(22)
|
|
(22)
|
|
102
|
|
(30)
|
|
(25)
|
|
Other General Medicines
|
839
|
|
(7)
|
|
(2)
|
|
53
|
|
(42)
|
|
(41)
|
|
180
|
|
(2)
|
|
1
|
|
606
|
|
(4)
|
|
2
|
|
Augmentin
|
186
|
|
5
|
|
10
|
|
–
|
|
–
|
|
–
|
|
54
|
|
(4)
|
|
(2)
|
|
132
|
|
9
|
|
16
|
|
Lamictal
|
101
|
|
(22)
|
|
(19)
|
|
37
|
|
(44)
|
|
(42)
|
|
28
|
|
–
|
|
4
|
|
36
|
|
3
|
|
9
|
|
Other
"Other General Medicines"
|
552
|
|
(8)
|
|
(3)
|
|
16
|
|
(38)
|
|
(38)
|
|
98
|
|
(1)
|
|
1
|
|
438
|
|
(8)
|
|
(1)
|
|
General Medicines
|
2,564
|
|
(4)
|
|
1
|
|
916
|
|
(1)
|
|
3
|
|
541
|
|
(3)
|
|
(1)
|
|
1,107
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
Commercial Operations turnover
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
Three months ended 31 March 2024
|
7,363
|
|
6
|
|
10
|
|
3,589
|
|
10
|
|
14
|
|
1,621
|
|
(5)
|
|
(3)
|
|
2,153
|
|
9
|
|
16
|
|
|
|
|
|
|
|
Commercial Operations turnover excluding COVID-19
solutions
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
Three
months ended 31 March 2024
|
7,362
|
|
8
|
|
13
|
|
3,589
|
|
10
|
|
14
|
|
1,621
|
|
1
|
|
3
|
|
2,152
|
|
11
|
|
18
|
|
Segment information
|
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the GSK
Leadership Team (GLT). GSK reports results under two segments:
Commercial Operations and Total R&D. Members of the GLT are
responsible for each segment.
R&D
investment is essential for the sustainability of the business.
However, for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and is reported as a separate segment. The operating costs
of this segment includes R&D activities across Specialty
Medicines, including HIV and Vaccines. It includes R&D and some
SG&A costs relating to regulatory and other
functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
|
|
|
|
|
|
|
|
|
|
Turnover by segment
|
|||||||
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
7,363
|
|
6,951
|
|
6
|
|
10
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,855
|
|
3,375
|
|
14
|
|
21
|
|
Research
and Development
|
(1,308)
|
|
(1,232)
|
|
6
|
|
9
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,547
|
|
2,143
|
|
19
|
|
28
|
|
Corporate
and other unallocated costs
|
(104)
|
|
(51)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
2,443
|
|
2,092
|
|
17
|
|
27
|
|
Adjusting
items
|
(953)
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
1,490
|
|
2,082
|
|
(28)
|
|
(18)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
32
|
|
29
|
|
|
|
|
|
Finance
costs
|
(166)
|
|
(203)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and
joint ventures
|
(1)
|
|
(2)
|
|
|
|
|
|
Profit/(loss)
on disposal of associates and joint ventures
|
–
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
1,355
|
|
1,907
|
|
(29)
|
|
(18)
|
Commercial
Operations Core operating profit of £3,855 million grew in the
quarter driven by strong sales and a favourable product mix and a
reversal of the Zejula
royalty dispute legal provision, partly offset by disciplined
investment in growth assets and lower royalty income.
The
R&D segment operating expenses of £1,308
million, grew in the quarter driven by continued investment
across disease areas including late stage investment in Vaccines,
Respiratory/Immunology and Infectious Diseases, including
pneumococcal and mRNA programmes, and camlipixant. This was partly
offset by decreases related to the completion of late-stage
clinical development programmes including RSV and momelotinib, and
reduced investment in Zejula versus Q1 2023. In the quarter
restructuring of the research division was broadly completed, with
the charge being taken in Q4 2023.
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2023. At 31 March
2024, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on page 10) was
£312 million (31 December 2023: £267
million).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
legal developments since the date of the Annual Report
2023:
Intellectual Property
RSV
The
United States District Court for the District of Delaware has set a
trial date of 3 August 2026 in the suit against Pfizer Inc.
alleging infringement of US GSK patents by Pfizer’s RSV
vaccine, ABRYSVO.
mRNA
On 25
April 2024, GSK filed a patent infringement suit against Pfizer
Inc. and BioNTech SE in the United States District Court for the
District of Delaware alleging infringement of five US GSK patents
by the COVID-19 vaccine, COMIRNATY.
Product Liability
Zantac
The
Delaware Superior Court held a hearing regarding admissibility of
expert testimony as to general causation on 22-24 January
2024. The parties continue to await a ruling from the Court,
which will relate only to the admissibility of evidence and not to
the determination of liability or to the merits of the underlying
claims.
As
announced on 29 February 2024, GSK reached a confidential
settlement in the Boyd/Steenvoord case filed in California state
court. The case, which was set to begin trial on 2 April 2024, will
be dismissed. The settlement reflects the company’s desire to
avoid the distraction related to protracted litigation in this
case. GSK did not admit any liability in the settlement and will
continue to vigorously defend itself based on the facts and the
science in all other Zantac
cases.
In the
California Judicial Council Coordination Proceedings (JCCP), the
Court has scheduled a Sargon hearing for 6-7 June 2024 for eight
cases, including two bellwether cases (Hughes and Caratti, cases
alleging colorectal and bladder cancer, respectively). The Court
has set a trial date for the Hughes case of 8 July 2024, with
Caratti to receive a trial date only after the Hughes trial
concludes. The other six cases do not have trial dates pending
their transfer to other counties in California. A separate Sargon
hearing for a further 12 cases has been set for 15 August 2024. The
Court has also ordered the parties to work up 350 cases for
trial.
Trial
dates have also been set in other state courts. In Illinois, the
first case scheduled for trial (Valadez, a case alleging colorectal
cancer) began on 30 April 2024 and is expected to last around four
weeks. The second Illinois case (Williams, a case alleging lung
cancer) is scheduled for trial on 23 May 2024. Three other cases
have trial dates in Illinois ahead of the expected publication date
of GSK's results for Q2 2024 (Gross and Kasza, cases alleging
prostate and breast cancer, respectively on 5 June 2024 and
Kimbrow, a case alleging prostate cancer, on 12 July 2024). On 16
April 2024, the Illinois court issued a Frye ruling in Valadez,
finding that the plaintiff’s experts’ causation
opinions are admissible and can be presented to a jury. The
single case in Texas is set for trial on 21 October 2024 and one
case in Nevada is scheduled for trial on 3 March
2025.
Given
the current stage of the proceedings, GSK cannot meaningfully
assess what liability, if any, it may have, nor can it meaningfully
assess the liability of other parties under relevant
indemnification provisions.
Returns to
shareholders
Quarterly dividends
The
Board has declared a first interim dividend for Q1 2024 of 15p per
share (Q1 2023: 14p per share).
Dividends
remain an essential component of total shareholder return and GSK
recognises the importance of dividends to shareholders. On 23 June
2021, at the GSK Investor Update, GSK set out that from 2022 a
progressive dividend policy will be implemented guided by a 40 to
60 percent pay-out ratio through the investment cycle. Consistent
with this, GSK has declared a dividend of 15p for Q1 2024 and
expects to declare a dividend of 60p per share for full year 2024.
In setting its dividend policy, GSK considers the capital
allocation priorities of the Group and its investment strategy for
growth alongside the sustainability of the dividend.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 9 July 2024. An annual fee
of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the
Depositary. The ex-dividend date will be 16 May 2024, with a record
date of 17 May 2024 and a payment date of 11 July
2024.
|
|
|
|
|
|
|
|
|
Paid/
Payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
|
|
2024
|
|
|
|
|
|
|
First
interim
|
11 July
2024
|
|
15
|
|
612
|
|
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
|
First
interim
|
13 July
2023
|
|
14
|
|
567
|
|
Second
interim
|
12
October 2023
|
|
14
|
|
568
|
|
Third
interim
|
11
January 2024
|
|
14
|
|
568
|
|
Fourth
interim
|
11
April 2024
|
|
16
|
|
652
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
2,355
|
Share capital in issue
At 31
March 2024, 4,078 million shares (Q1 2023: 4,052 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). No Treasury shares have been repurchased since 2014. The
company issued 1.9 million shares under employee share schemes in
the year for proceeds of £18 million (Q1 2023:
£8 million).
At 31
March 2024, the ESOP Trusts held 66.9 million shares of GSK shares,
of which 66.6 million were held for the future exercise of share
options and share awards and 0.3 million were held for the
Executive Supplemental Savings plan. The carrying value of
£611 million has been deducted from other reserves. The
market value of these shares was
£1,144 million.
At 31
March 2024, the company held 169 million Treasury shares at a cost
of £2,957 million which has been deducted from retained
earnings.
Weighted average number of shares
The
numbers of shares used in calculating basic and diluted earnings
per share are reconciled below:
|
|
|
|
|
|
|
|
|
|
|
Q1 2024
millions
|
|
Q1
2023
millions
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,069
|
|
4,044
|
|
Dilutive
effect of share options and share awards
|
|
|
44
|
|
41
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
4,113
|
|
4,085
|
Additional
information
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the three months ended 31 March 2024 and should be
read in conjunction with the Annual Report 2023, which was prepared
in accordance with United Kingdom adopted International Financial
Reporting Standards. This Results Announcement has been prepared
applying consistent accounting policies to those applied by the
Group in the Annual Report 2023.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2023.
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2023 were published
in the Annual Report 2023, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
Exchange rates
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
|
|
|
|
|
|
Q1 2024
|
|
Q1
2023
|
|
2023
|
||
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.27
|
|
1.22
|
|
1.24
|
|
|
|
Euro/£
|
1.16
|
|
1.14
|
|
1.15
|
|
|
|
Yen/£
|
187
|
|
162
|
|
175
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.26
|
|
1.24
|
|
1.27
|
|
|
|
Euro/£
|
1.17
|
|
1.14
|
|
1.15
|
|
|
|
Yen/£
|
191
|
|
165
|
|
180
|
Contingent liabilities
There
were contingent liabilities at 31 March 2024 in respect of
arrangements entered into as part of the ordinary course of the
Group’s business. No material losses are expected to arise
from such contingent liabilities. Provision is made for the outcome
of legal and tax disputes where it is both probable that the Group
will suffer an outflow of funds and it is possible to make a
reliable estimate of that outflow. Descriptions of the significant
legal disputes to which the Group is a party are set out on page 32
and pages 263 to 266 of the 2023 Annual Report.
Net assets
The
book value of net assets increased by £434 million from
£12,795 million at 31 December 2023 to £13,229 million at
31 March 2024. This primarily reflected contribution from Total
comprehensive income for the period partly offset by dividends paid
to shareholders.
At 31
March 2024, the net deficit on the Group’s pension plans was
£721 million compared with £764 million at 31 December
2023. This decrease in the net deficit is primarily due to
increases in the UK and US discount rates, as well as experience
adjustments, partially offset by lower UK asset values and an
increase to the US cash balance credit rate.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £914 million (31 December
2023: £848 million).
Contingent
consideration amounted to £7,075 million at 31 March 2024 (31
December 2023: £6,662 million), of which £6,004 million
(31 December 2023: £5,718 million) represented the estimated
present value of amounts payable to Shionogi relating to ViiV
Healthcare, £446 million (31 December 2023: £423 million)
represented the estimated present value of contingent consideration
payable to Novartis related to the Vaccines acquisition, £527
million (31 December 2023: £516 million) represented the
estimated present value of contingent consideration payable to
Affinivax, and £95 million (31 December 2023: £nil)
represented the estimated present value of contingent consideration
payable in relation to the Aiolos acquisition. Of the contingent
consideration payable to Shionogi at 31 March 2024, £1,057
million (31 December 2023: £1,017 million) is expected to be
paid within one year.
Movements
in contingent consideration are as follows:
|
|
|
|
|
|
Q1 2024
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,718
|
|
6,662
|
|
Remeasurement
through income statement and other movements
|
586
|
|
722
|
|
Cash
payments: operating cash flows
|
(300)
|
|
(306)
|
|
Cash
payments: investing activities
|
–
|
|
(3)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
6,004
|
|
7,075
|
|
|
|
|
|
|
Q1
2023
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,890
|
|
7,068
|
|
Remeasurement
through income statement and other movements
|
(64)
|
|
(193)
|
|
Cash
payments: operating cash flows
|
(287)
|
|
(290)
|
|
Cash
payments: investing activities
|
–
|
|
(1)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,539
|
|
6,584
|
Business acquisitions
On 9
January 2024, GSK announced it had entered into an agreement to
acquire Aiolos Bio, Inc. (Aiolos) a clinical stage
biopharmaceutical company focused on addressing the unmet treatment
needs of patients with certain respiratory and inflammatory
conditions, for a total consideration of US$1,004 million
(£800 million) as adjusted for working capital acquired paid
upon closing and up to US$400 million (£319 million) in
certain success-based regulatory milestone payments. The estimated
fair value of the contingent consideration payable was US$120
million (£96 million). In addition, GSK will also be
responsible for success-based milestone payments as well as tiered
royalties owed to Jiangsu Hengrui Pharmaceuticals Co., Ltd.
(Hengrui). The acquisition completed on 14 February
2024.
The
initial acquisition accounting was reflected in the first quarter
of 2024 on a preliminary basis, the values below are provisional
and subject to change. The purchase price allocation is expected to
be completed by the end of Q4 2024.
The
provisional fair values of the net assets acquired, including
goodwill, are as follows:
|
|
|
|
|
|
|
|
|
£m
|
|
|
|
|
|
|
Net
assets acquired:
|
|
|
|
|
Intangible
assets
|
|
|
927
|
|
Cash
and cash equivalents
|
|
|
23
|
|
Other
net liabilities
|
|
|
(16)
|
|
Deferred
tax liabilities
|
|
|
(197)
|
|
|
|
|
|
|
|
|
|
737
|
|
Goodwill
|
|
|
159
|
|
|
|
|
|
|
Total
consideration
|
|
|
896
|
|
|
|
|
|
|
|
|
Of the
£896 million consideration, £154 million was unpaid as at
31 March 2024.
|
|||||
|
|
|
||||
|
Net debt information
|
|
||||
|
|
|
|||||||
|
Reconciliation of cash flow to movements in net debt
|
|
|||||||
|
|
|
|
|
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
|
|
|
|
|
Total
Net debt at beginning of the period
|
(15,040)
|
|
(17,197)
|
|
|
|
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
(251)
|
|
(673)
|
|
(Increase)/decrease
in liquid investments
|
(22)
|
|
–
|
|
Net
increase/(repayment) of other short-term loans
|
323
|
|
(552)
|
|
Repayment
of long-term notes
|
–
|
|
144
|
|
Repayment
of lease liabilities
|
57
|
|
47
|
|
Exchange
adjustments
|
1
|
|
322
|
|
Other
non-cash movements
|
(29)
|
|
(41)
|
|
|
|
|
|
|
Decrease/(increase)
in net debt
|
79
|
|
(753)
|
|
Total
Net debt at end of the period
|
(14,961)
|
|
(17,950)
|
|
|
|
Net debt analysis
|
|
|
|
|
|
|
|
31 March 2024
£m
|
|
31
December 2023
£m
|
|
|
|
|
|
|
Liquid
investments
|
21
|
|
42
|
|
Cash
and cash equivalents
|
2,790
|
|
2,936
|
|
Short-term
borrowings
|
(2,616)
|
|
(2,813)
|
|
Long-term
borrowings
|
(15,156)
|
|
(15,205)
|
|
|
|
|
|
|
Total
Net debt at the end of the period
|
(14,961)
|
|
(15,040)
|
|
|
||||
|
Free cash flow reconciliation
|
|
|
|
|
|
|
|
Q1 2024
£m
|
|
Q1
2023
£m
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities
|
958
|
|
53
|
|
Purchase
of property, plant and equipment
|
(248)
|
|
(233)
|
|
Proceeds
from sale of property, plant and equipment
|
1
|
|
7
|
|
Purchase
of intangible assets
|
(315)
|
|
(296)
|
|
Proceeds
from disposals of intangible assets
|
27
|
|
4
|
|
Net
finance costs
|
(34)
|
|
(91)
|
|
Dividends
and disposal proceeds from associates and joint
ventures
|
–
|
|
1
|
|
Contingent
consideration paid (reported in investing activities)
|
(3)
|
|
(1)
|
|
Distributions
to non-controlling interests
|
(97)
|
|
(140)
|
|
Contributions
from non-controlling interests
|
–
|
|
7
|
|
|
|
|
|
|
Free
cash inflow/(outflow)
|
289
|
|
(689)
|
Related party transactions
Details
of GSK’s related party transactions are disclosed on page 235
of our 2023 Annual Report.
|
|
|
R&D commentary
|
|
|
|
Pipeline overview
|
|
|
|
|
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
18
|
Infectious Diseases (7)
|
|
|
●
|
Arexvy (RSV vaccine) RSV older adults (50-59 years of
age)
|
||
|
●
|
gepotidacin
(bacterial topoisomerase inhibitor) uncomplicated urinary tract
infection and urogenital gonorrhoea
|
||
|
●
|
bepirovirsen
(HBV ASO) hepatitis B virus
|
||
|
●
|
Bexsero infants vaccine (US)
|
||
|
●
|
MenABCWY
(gen 1) vaccine candidate
|
||
|
●
|
tebipenem
pivoxil (antibacterial carbapenem) complicated urinary tract
infection
|
||
|
●
|
ibrexafungerp
(antifungal glucan synthase inhibitor) invasive
candidiasis
|
||
|
|
|
|
|
|
|
|
Respiratory/Immunology (6)
|
|
|
|
|
●
|
Nucala (anti-IL5 biologic) chronic obstructive pulmonary
disease
|
|
|
|
●
|
depemokimab
(ultra long-acting anti-IL5 biologic) severe eosinophilic asthma,
eosinophilic granulomatosis with polyangiitis (EGPA), chronic
rhinosinusitis with nasal polyps (CRSwNP), hyper-eosinophilic
syndrome (HES)
|
|
|
|
●
|
latozinemab
(AL001, anti-sortilin) frontotemporal dementia
|
|
|
|
●
|
camlipixant
(P2X3 receptor antagonist) refractory chronic cough
|
|
|
|
●
|
Ventolin (salbutamol, Beta 2 adrenergic receptor agonist)
asthma
|
|
|
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
|
|
|
|
|
|
|
|
Oncology (5)
|
|
|
|
|
●
|
Ojjaara (JAK1, JAK2 and ACVR1 inhibitor) myelofibrosis with
anaemia
|
|
|
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
|
|
|
●
|
Jemperli (anti-PD-1) 1L endometrial cancer, colon cancer,
rectal cancer, head and neck cancer
|
|
|
|
●
|
Zejula (PARP inhibitor) 1L ovarian and non-small cell lung
cancer
|
|
|
|
●
|
cobolimab
(anti-TIM-3) 2L non-small cell lung cancer
|
|
|
|
|
|
|
Total
vaccines and medicines in all phases of clinical
development
|
72
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
91
|
|
|
Our key growth assets by therapy area
The
following outlines several key vaccines and medicines by therapy
area that will help drive growth for GSK to meet its outlooks for
2021-2026 and beyond.
Infectious Diseases
Arexvy (respiratory
syncytial virus vaccine, adjuvanted)
The US
Food and Drug Administration (FDA) accepted under Priority Review
an application to extend the indication of GSK’s adjuvanted
respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who
are at increased risk for RSV disease. If approved, GSK’s RSV
vaccine would be the first vaccine available to help protect this
population. Arexvy is
currently approved in the US in adults aged 60 and over for the
prevention of lower respiratory tract disease (LRTD) caused by
RSV.
Key
phase III trials for Arexvy:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV
OA=ADJ-004
(Adults
≥ 60 years old)
NCT04732871
|
III
|
A
randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial
start:
Q1
2021
Primary
data reported:
Q2
2022
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-006
(ARESVI-006;
Adults ≥ 60 years old)
NCT04886596
|
III
|
A
randomised, placebo-controlled, observer-blind, multi-country trial
to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial
start:
Q2
2021
Primary
data reported:
Q2
2022;
two
season data reported:
Q2
2023
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-007
(Adults
≥ 60 years old)
NCT04841577
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with FLU-QIV vaccine
in adults aged 60 years and above
|
Trial
start:
Q2
2021
Primary
data reported:
Q4
2022
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-008
(Adults
≥ 65 years old)
NCT05559476
|
III
|
A phase
III, open-label, randomised, controlled, multi country trial to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU HD vaccine
in adults aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete
|
|
RSV
OA=ADJ-009
(Adults
≥ 60 years old)
NCT05059301
|
III
|
A
randomised, double-blind, multi-country trial to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial
start:
Q4
2021
Trial
end:
Q2
2022
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-017
(Adults
≥ 65 years old)
NCT05568797
|
III
|
A phase
III, open-label, randomised, controlled, multi-country trial to
evaluate the immune response, safety and reactogenicity of an
RSVPreF3 OA investigational vaccine when co-administered with FLU
aQIV (inactivated influenza vaccine – adjuvanted) in adults
aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete
|
|
RSV
OA=ADJ-018
(Adults
50-59 years)
NCT05590403
|
III
|
A phase
III, observer-blind, randomised, placebo-controlled trial to
evaluate the non-inferiority of the immune response and safety of
the RSVPreF3 OA investigational vaccine in adults 50-59 years of
age, including adults at increased risk of respiratory syncytial
virus lower respiratory tract disease, compared to older adults
≥60 years of age
|
Trial
start:
Q4
2022
Primary
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-019
(Adults
≥ 60 years old)
NCT05879107
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with PCV20 in adults
aged 60 years and older
|
Trial
start:
Q2
2023
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
|
RSV
OA=ADJ-023
(Immunocompromised
Adults 50-59 years)
NCT05921903
|
IIb
|
A
randomised, controlled, open-label trial to evaluate the immune
response and safety of the RSVPreF3 OA investigational vaccine in
adults (≥50 years of age) when administered to lung and renal
transplant recipients comparing one versus two doses and compared
to healthy controls (≥50 years of age) receiving one
dose
|
Trial
start:
Q3
2023
Data
anticipated: 2025
|
Active,
recruiting
|
|
RSV-OA=ADJ-020
(Adults, aged >=50 years of age)
NCT05966090
|
III
|
A study
on the safety and immune response of investigational RSV OA vaccine
in combination with herpes zoster vaccine in healthy
adults
|
Trial
start:
Q3
2023
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
bepirovirsen (HBV ASO)
Bepirovirsen,
a triple-action antisense oligonucleotide, is a potential new
treatment option for people with chronic hepatitis B (CHB). In
February 2024, the US FDA granted Fast Track designation for
bepirovirsen for the treatment of CHB. Fast Track designation is
intended to facilitate the development and expedite the review of
medicines to treat serious conditions and fill an unmet medical
need. To further expand development in novel sequential regimens,
GSK has entered an agreement for an exclusive worldwide license to
develop and commercialise daplusiran/tomligisiran (GSK5637608,
formerly JNJ-3989), an investigational hepatitis B virus-targeted
small interfering ribonucleic acid (siRNA) therapeutic. This
agreement provides an opportunity to investigate a novel sequential
regimen to pursue functional cure in an even broader patient
population with bepirovirsen.
Key
trials for bepirovirsen:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Well
1 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630807
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
Data
anticipated: 2026+
|
Recruiting
|
|
B-Well
2 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630820
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
Data
anticipated: 2026+
|
Recruiting
|
|
bepirovirsen
sequential combination therapy with targeted
immunotherapy
(chronic
hepatitis B)
NCT05276297
|
II
|
A trial
on the safety, efficacy and immune response following sequential
treatment with an anti-sense oligonucleotide against chronic
hepatitis B (CHB) and chronic hepatitis B targeted immunotherapy
(CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA)
therapy
|
Trial
start:
Q2
2022
Data
anticipated: 2025
|
Active,
not recruiting
|
gepotidacin (bacterial topoisomerase inhibitor)
Gepotidacin
is an investigational bactericidal, first-in-class antibiotic with
a novel mechanism of action for the treatment of uncomplicated
urinary tract infections (uUTI). In February 2024, positive
headline results were announced from the pivotal EAGLE-1 phase III
trial for gepotidacin showing the primary endpoint was met.
Gepotidacin achieved a 92.6% microbiological success rate compared
to a 91.2% success rate of intramuscular ceftriaxone plus oral
azithromycin combined therapy (a leading combination treatment
regimen for gonorrhoea), demonstrating non-inferiority. Safety and
tolerability data were consistent with results seen in gepotidacin
phase I and II trials. The data were presented at the 2024 European
Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Global in April 2024.
EAGLE-1
is the third positive pivotal trial for gepotidacin and
demonstrates its potential to provide a new oral treatment option
for patients given the rising incidence of gonorrhoea worldwide,
including drug resistant infections.
Key
phase III trials for gepotidacin:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1
(uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A
randomised, multi-centre, open-label trial in adolescent and adult
participants comparing the efficacy and safety of gepotidacin to
ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria gonorrhoeae
|
Trial
start:
Q4
2019
Data
reported:
Q1
2024
|
Complete;
primary
endpoint met
|
|
EAGLE-2
(females with uUTI / acute cystitis)
NCT04020341
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q4
2019
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
|
EAGLE-3
(females with uUTI / acute cystitis)
NCT04187144
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q2
2020
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
MenABCWY vaccine candidate
The US
FDA accepted a Biologics License Application (BLA) for GSK’s
5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate on 16 April
2024 and set a Prescription Drug User Fee Act (PDUFA) action date
of 14 February 2025. GSK’s MenABCWY vaccine candidate
combines the antigenic components of its two well-established
meningococcal vaccines with demonstrated efficacy and safety
profiles, Bexsero
(Meningococcal Group B Vaccine) and Menveo (Meningococcal Groups A, C, Y,
and W-135). Combining the protection offered by these vaccines aims
to reduce the number of injections, simplifying immunisation and
potentially increasing series completion and vaccination coverage
of adolescents and young adults.
Key
trials for MenABCWY vaccine candidate:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MenABCWY
– 019
NCT04707391
|
IIIb
|
A
randomised, controlled, observer-blind trial to evaluate safety and
immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial
start:
Q1
2021
Data
reported:
Q1
2024
|
Complete
|
|
MenABCWY
– V72 72
NCT04502693
|
III
|
A
randomised, controlled, observer-blind trial to demonstrate
effectiveness, immunogenicity, and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
Data
reported:
Q1
2023
|
Complete;
primary endpoints met
|
HIV
cabotegravir
GSK
continues to advance its early-stage HIV pipeline focused on
innovative long-acting injectable regimens and expects cabotegravir
to increasingly replace dolutegravir as the foundational integrase
inhibitor in its portfolio by the second half of the decade. In
February 2024, ViiV Healthcare announced results from an interim
analysis of the LATITUDE phase III trial after the trial’s
Data Safety Monitoring Board recommended it be modified to stop
randomisation and give participants receiving daily oral therapy
the option to transition to long-acting injectable therapy. Results
indicated that long-acting injectable antiretroviral treatment
(ART) for HIV, Cabenuva
(cabotegravir + rilpirivine), demonstrated superior efficacy in
maintaining viral load suppression compared to daily oral therapy
in individuals with a history of ART adherence
challenges.
In
March 2024, ViiV Healthcare presented 64 abstracts at the
Conference on Retroviruses and Opportunistic Infections (CROI), in
Denver, Colorado, including highlights of the company’s
next-generation pipeline advancements and data from its diverse
portfolio of marketed HIV treatment and prevention options.
Detailed results from the LATITUDE trial were presented, together
with positive findings from a phase I study showing that an
investigational formulation of cabotegravir, known as cabotegravir
ultra long-acting (CAB-ULA), can be dosed at intervals of at least
four months. This is the company’s first step towards
delivering ultra long-acting injectable HIV treatment and
prevention medicines that would potentially enable people to have
at least four months between visits to the clinic.
Respiratory/Immunology
camlipixant (P2X3 receptor antagonist)
Camlipixant
(BLU-5937) is an investigational, highly selective oral P2X3
antagonist currently in development for first-line treatment of
adult patients suffering from refractory chronic cough (RCC). The
CALM phase III development programme to evaluate the efficacy and
safety of camlipixant for use in adults with RCC is
ongoing.
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
CALM-1
(refractory chronic cough)
NCT05599191
|
III
|
A
52-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q4
2022
Data
anticipated:
2025
|
Recruiting
|
|
CALM-2
(refractory chronic cough)
NCT05600777
|
III
|
A
24-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q1
2023
Data
anticipated:
2025
|
Recruiting
|
depemokimab (long acting anti-IL5)
Depemokimab
is in late stage development for severe asthma, chronic
rhinosinusitis with nasal polyps (CRSwNP), hypereosinophilic
syndrome (HES) and eosinophilic granulomatosis with polyangiitis
(EGPA). Depemokimab is the first and only next-generation
ultra-long-acting biologic engineered to have enhanced binding
affinity and high potency for IL-5, resulting in an extended
half-life and enabling dosing every six months.
The
phase III programme for depemokimab continues to make progress
across a range of IL-5 mediated conditions with phase III data
expected to begin reading out in H1 2024.
Key
phase III trials for depemokimab:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1
(severe eosinophilic asthma)
NCT04719832
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
anticipated:
H1
2024
|
Active,
not recruiting
|
|
SWIFT-2
(severe eosinophilic asthma)
NCT04718103
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
anticipated:
H1
2024
|
Active,
not recruiting
|
|
|
|
Key
phase III trials for depemokimab continued:
|
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
AGILE
(SEA)
NCT05243680
|
III
(exten
sion)
|
A
52-week, open label extension phase of SWIFT-1 and SWIFT-2 to
assess the long-term safety and efficacy of depemokimab adjunctive
therapy in adult and adolescent participants with severe
uncontrolled asthma with an eosinophilic phenotype
|
Trial
start:
Q1
2022
Data
anticipated:
2025
|
Recruiting
|
|
NIMBLE
(SEA)
NCT04718389
|
III
|
A
52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial
start:
Q1
2021
Data
anticipated:
2025
|
Recruiting
|
|
ANCHOR-1
(chronic rhinosinusitis with nasal polyps; CRSwNP)
NCT05274750
|
III
|
Efficacy
and safety of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
|
ANCHOR-2
(CRSwNP)
NCT05281523
|
III
|
Efficacy
and safety of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
|
OCEAN
(eosinophilic granulomatosis with polyangiitis; EGPA)
NCT05263934
|
III
|
Efficacy
and safety of depemokimab compared with mepolizumab in adults with
relapsing or refractory EGPA
|
Trial
start:
Q3
2022
Data
anticipated:
2025
|
Recruiting
|
|
DESTINY
(hyper-eosinophilic syndrome; HES)
NCT05334368
|
III
|
A
52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care (SoC) therapy
|
Trial
start:
Q3
2022
Data
anticipated:
2026+
|
Recruiting
|
Nucala (mepolizumab)
Nucala, is a first in class anti-IL-5 biologic. It been
studied in over 4,000 patients in 41 clinical trials across several
IL-5 mediated conditions. Nucala is the only treatment approved
for use in the US and Europe, across four IL-5 medicated
conditions: severe asthma with an eosinophilic phenotype, EGPA, HES
and CRSwNP.
The
MATINEE phase III trial investigating Nucala in patients with chronic
obstructive pulmonary disease (COPD) is expected to readout in the
second half of 2024.
Key
phase trials for Nucala:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MATINEE
(chronic obstructive pulmonary disease; COPD)
NCT04133909
|
III
|
A
multicentre randomised, double-blind, parallel-group,
placebo-controlled trial of mepolizumab 100 mg subcutaneously as
add-on treatment in participants with COPD experiencing frequent
exacerbations and characterised by eosinophil levels
|
Trial
start:
Q4
2019
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
Oncology
Blenrep (belantamab
mafodotin)
In
February 2024, GSK presented positive results from the DREAMM-7
phase III head-to-head trial evaluating belantamab mafodotin as a
second-line or later treatment for relapsed or refractory multiple
myeloma at the American Society of Clinical Oncology (ASCO) Plenary
Series. The trial met its primary endpoint of progression-free
survival (PFS), with a statistically significant and clinically
meaningful 59% reduction in risk of disease progression or
death observed in patients with belantamab mafodotin combined with
bortezomib plus dexamethasone (BorDex) versus standard of care,
daratumumab plus BorDex. A median PFS of 36.6 months was observed
with the belantamab mafodotin combination versus 13.4 months with
the daratumumab combination. The belantamab mafodotin combination
also resulted in clinically meaningful improvements in all
secondary efficacy endpoints including a doubling of complete
response rate (stringent complete response plus complete response),
minimal residual disease negativity rate and median duration of
response. A strong and clinically meaningful overall survival (OS)
trend was observed at the interim analysis, with a 43% reduction in
the risk of death. OS follow-up continues and further analyses are
planned.
In
March 2024, GSK announced positive headline results from a planned
interim analysis of the DREAMM-8 phase III head-to-head trial
evaluating belantamab mafodotin, in combination with pomalidomide
plus dexamethasone (PomDex), versus a standard of care, bortezomib
plus PomDex, as a second line and later treatment for relapsed or
refractory multiple myeloma. The trial met its primary endpoint of
PFS, with the belantamab mafodotin combination significantly
extending the time to disease progression or death versus the
standard of care combination. A positive OS trend favouring the
belantamab mafodotin combination was also observed at the time of
this analysis. The trial continues to follow up for
OS.
Results
from DREAMM-8 will be presented at ASCO 2024, and data from both
DREAMM-7 and DREAMM-8 are being shared with health
authorities.
The
DREAMM (DRiving Excellence in Approaches to Multiple Myeloma)
clinical development programme continues to evaluate the potential
of belantamab mafodotin in early lines of treatment and in
combination with novel therapies and standard of care
treatments.
Key
phase III trials for Blenrep:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-7
(2L+ multiple myeloma; MM)
NCT04246047
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of the combination of belantamab mafodotin, bortezomib,
and dexamethasone (B-Vd) compared with the combination of
daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial
start:
Q2
2020
Primary
data reported:
Q4
2023
|
Active,
not recruiting
|
|
DREAMM-8
(2L+ MM)
NCT04484623
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin in combination with pomalidomide
and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and
dexamethasone (P-Vd) in participants with relapsed/refractory
multiple myeloma
|
Trial
start:
Q4
2020
Primary
data reported:
Q1
2024
|
Primary
endpoint met
|
Jemperli (dostarlimab)
Jemperli is the foundation of GSK’s ongoing
immuno-oncology-based research and development programme. It is
currently approved in the US and several other countries in a
subset of adult patients with primary advanced or recurrent
endometrial cancer that is mismatch repair deficient (dMMR), or
microsatellite instability-high (MSI-H). Efforts continue to
generate data to support combination therapies with dostarlimab as
the backbone and expand use into a broader population of
patients.
In
March 2024, GSK presented statistically significant and clinically
meaningful OS results from Part 1 of the RUBY phase III trial in
adult patients with primary advanced or recurrent endometrial
cancer at the Society of Gynecologic Oncology 2024 Annual Meeting
on Women’s Cancer (SGO 2024). A 31% reduction in the risk of
death and 16.4-month improvement in median OS was observed with
dostarlimab plus chemotherapy versus chemotherapy in the overall
population. Dostarlimab plus chemotherapy is the only
immuno-oncology combination to show statistically significant and
clinically meaningful OS in patients with primary advanced or
recurrent endometrial cancer, regardless of biomarker
status.
In
April 2024, the US FDA accepted under Priority Review a
supplemental Biologics License Application (sBLA) for Jemperli in combination with
standard-of-care chemotherapy (carboplatin and paclitaxel) for the
treatment of adult patients with primary advanced or recurrent
endometrial cancer based on the RUBY Part 1 data. The Prescription
Drug User Fee Act action date is 23 August 2024. Approval of the
sBLA would broaden the current indication for Jemperli plus chemotherapy to all adult
patients with primary advanced or recurrent endometrial cancer,
including patients with mismatch repair proficient
(MMRp)/microsatellite stable (MSS) tumours.
GSK
also presented PFS results from Part 2 of the RUBY phase III trial
in primary advanced or recurrent endometrial cancer at SGO 2024. In
RUBY Part 2, a 37% reduction in risk of disease progression or
death and 6-month improvement in median PFS was observed with the
addition of Zejula
(niraparib) to dostarlimab maintenance following dostarlimab plus
chemotherapy versus chemotherapy in patients with MMRp)/MSS
tumours.
In
March 2024, GSK began recruiting for its phase III JADE clinical
trial evaluating the safety and effectiveness of dostarlimab in
adult participants with locally advanced unresectable head and neck
squamous cell carcinoma.
Key
trials for Jemperli:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
(1L stage III or IV endometrial cancer)
NCT03981796
|
III
|
A
randomised, double-blind, multi-centre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial
start:
Q3
2019
Part 1
data reported:
Q4
2022
Part 2
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoints met
|
|
PERLA
(1L metastatic non-small cell lung cancer)
NCT04581824
|
II
|
A
randomised, double-blind trial to evaluate the efficacy of
dostarlimab plus chemotherapy versus pembrolizumab plus
chemotherapy in metastatic non-squamous non-small cell lung
cancer
|
Trial
start:
Q4
2020
Primary
data reported:
Q4
2022
|
Active,
not recruiting; primary endpoint met
|
|
GARNET
(advanced solid tumours)
NCT02715284
|
I/II
|
A
multi-centre, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumours who have
limited available treatment options
|
Trial
start:
Q1
2016
Primary
data reported:
Q1
2019
|
Recruiting
|
|
AZUR-1
(locally advanced rectal cancer)
NCT05723562
|
II
|
A
single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial
start:
Q1
2023
Data
anticipated: 2026
|
Recruiting
|
|
AZUR-2
(untreated perioperative T4N0 or stage III colon
cancer)
NCT05855200
|
III
|
An
open-label, randomised trial of perioperative dostarlimab
monotherapy versus standard of care in participants with untreated
T4N0 or stage III dMMR/MSI-H resectable colon cancer
|
Trial
start:
Q2
2023
Data
anticipated: 2026+
|
Recruiting
|
|
COSTAR
Lung (advanced non-small cell lung cancer that has progressed on
prior PD-(L)1 therapy and chemotherapy)
NCT04655976
|
II/III
|
A
multi-centre, randomised, parallel group treatment, open label
trial comparing cobolimab + dostarlimab + docetaxel to dostarlimab
+ docetaxel to docetaxel alone in participants with advanced
non-small cell lung cancer who have progressed on prior
anti-PD-(L)1 therapy and chemotherapy
|
Trial
start:
Q4
2020
Data
anticipated:
2025
|
Active,
not recruiting
|
|
JADE
(locally advanced unresected head and neck cancer)
NCT06256588
|
III
|
A
randomised, double-blind, study to evaluate dostarlimab versus
placebo as sequential therapy after chemoradiation in participants
with locally advanced unresected head and neck squamous cell
carcinoma
|
Trial
start:
Q1
2024
Data
anticipated: 2026+
|
Recruiting
|
Ojjaara/Omjjaara (momelotinib)
Following
the September 2023 approval of Ojjaara by the US FDA and its
authorisation as Omjjara by
the European Commission and the UK Medicines & Healthcare
products Regulatory Agency (MHRA) in January 2024, GSK continues to
pursue regulatory submissions and approvals in myelofibrosis across
the globe, including a new drug application under review in Japan.
With its differentiated mechanism of action, Ojjaara has the potential to become a
backbone therapy in myelofibrosis, and GSK continues to evaluate
its potential in combinations and other areas of unmet
need.
Key
phase III trial for momelotinib:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MOMENTUM
(myelofibrosis)
NCT04173494
|
III
|
A
randomised, double-blind, active control phase III trial intended
to confirm the differentiated clinical benefits of the
investigational drug momelotinib (MMB) versus danazol (DAN) in
symptomatic and anaemic subjects who have previously received an
approved Janus kinase inhibitor (JAKi) therapy for myelofibrosis
(MF)
|
Trial
start:
Q1
2020
Primary
data reported:
Q1
2022
|
Complete;
primary endpoint met
|
Zejula (niraparib)
GSK
continues to assess the potential of Zejula across multiple tumour types and
in combination with other agents. The ongoing development programme
includes several combination studies, including the RUBY Part 2
phase III trial of niraparib and dostarlimab, a programmed death
receptor-1 (PD-1)-blocking antibody, in recurrent or primary
advanced (stage III or IV) endometrial cancer, for which positive
results were presented at the Society of Gynecologic Oncology 2024
Annual Meeting on Women’s Cancer in March 2024.
Key
ongoing phase III trials for Zejula (see also RUBY Part 2 in
Jemperli
section):
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZEAL-1L
(1L advanced non-small cell lung cancer maintenance )
NCT04475939
|
III
|
A
randomised, double-blind, placebo-controlled, multi-centre trial
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial
start:
Q4
2020
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
|
FIRST
(1L ovarian cancer maintenance)
NCT03602859
|
III
|
A
randomised, double-blind, comparison of platinum-based therapy with
dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
non-mucinous epithelial ovarian cancer
|
Trial
start:
Q4
2018
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
Reporting
definitions
Total and Core results
Total
reported results represent the Group’s overall performance.
GSK uses a number of non-IFRS, measures to report the performance
of its business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for or superior
to, information presented in accordance with IFRS. Core results are
defined on page 18 and other non-IFRS measures are defined
below.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. For
those countries which qualify as hyperinflationary as defined by
the criteria set out in IAS 29 ‘Financial Reporting in
Hyperinflationary Economies’ (Argentina and Turkey) CER
growth is adjusted using a more appropriate exchange rate
reflecting depreciation of their respective currencies in order to
provide comparability and not to distort CER growth
rates.
£%
or AER% represents growth at actual exchange rates.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests,
contributions from non-controlling interests plus proceeds from the
sale of property, plant and equipment and intangible assets, and
dividends received from joint ventures and associates. The measure
is used by management as it is considered a good indicator of net
cash generated from business activities (excluding any cash flows
arising from equity investments, business acquisitions or disposals
and changes in the level of borrowing) available to pay
shareholders dividends and to fund strategic plans. Free cash flow
growth is calculated on a reported basis. A reconciliation of net
cash inflow from operations to free cash flow from operations is
set out on page 37.
Free cash flow conversion
Free
cash flow conversion is free cash flow from operations as a
percentage of profit attributable to shareholders.
Total Net debt
Net
debt is defined as total borrowings less cash, cash equivalents,
liquid investments, and short-term loans to third parties that are
subject to an insignificant risk of change in value. The measure is
used by management as it is considered a good indicator of GSK's
ability to meet its financial commitments and the strength of its
balance sheet.
COVID-19 solutions
COVID-19
solutions include the sales of pandemic adjuvant and other COVID-19
solutions during the years from 2020-2023 and includes vaccine
manufacturing and Xevudy
and the associated costs but does not include reinvestment in
R&D. This categorisation is used by management who believe it
is helpful to investors through providing clarity on the results of
the Group by showing the contribution to growth from COVID-19
solutions during this period.
Turnover excluding COVID-19 solutions
Turnover excluding COVID-19 solutions excludes the impact of sales
of pandemic adjuvant within Vaccines and Xevudy within Specialty Medicines related to the
COVID-19 pandemic during the years 2020-2023. Management believes
that the exclusion of the impact of these COVID-19 solutions sales
aids comparability in the reporting periods and understanding of
GSK’s growth including by region versus prior periods and
also 2024 Guidance which excludes any contributions from COVID-19
solutions in current year or comparator
periods.
Non-controlling interest
Non-controlling
interest is the equity in a subsidiary not attributable, directly
or indirectly, to a parent.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
Total Operating Margin
Total
Operating margin is Total operating profit divided by
turnover.
Core Operating Margin
Core
Operating margin is Core operating profit divided by
turnover.
Total Earnings per
share
Unless
otherwise stated, Total earnings per share refers to Total basic
earnings per share.
RAR (Returns and Rebates)
GSK
sells to customers both commercial and government mandated
contracts with reimbursement arrangements that include rebates,
chargebacks and a right of return for certain pharmaceutical
products principally in the US. Revenue recognition reflects
gross-to-net sales adjustments as a result. These adjustments are
known as the RAR accruals and are a source of significant
estimation uncertainty and fluctuation which can have a material
impact on reported revenue from one accounting period to the
next.
Risk adjusted sales
Pipeline
risk-adjusted sales are based on the latest internal estimate of
the probability of technical and regulatory success for each asset
in development.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines for inhaled respiratory, dermatology,
antibiotics and other diseases.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines for infectious diseases, HIV, Respiratory/Immunology and
Other and Oncology.
Percentage points
Percentage
points of growth which is abbreviated to ppts.
Brand names and partner acknowledgements: brand names appearing in
italics throughout this document are trademarks of GSK or
associated companies or used under licence by the
Group.
Guidance and outlooks, assumptions
and cautionary statements
2024 Guidance
GSK
expects 2024 sales to increase between 5 to 7 per cent but now
towards the upper part of the range and Core Operating profit to
increase between 9 to 11 percent (previously 7 to 10 per cent).
Core Earnings per share is expected to increase between 8 to 10
percent (previously 6 to 9 per cent).
The
Group continues to expect high single digit to low double-digit
growth for Vaccines, low double-digit growth for Specialty
Medicines and a mid-single-digit decrease for General
Medicines.
This
guidance is provided at CER and excludes any contribution from
COVID-19 related solutions.
Assumptions and basis of preparation related to 2024
guidance
In
outlining the guidance for 2024, the Group has made certain
planning assumptions about the macro-economic environment, the
healthcare sector (including regarding existing and possible
additional governmental legislative and regulatory reform), the
different markets and competitive landscape in which the Group
operates and the delivery of revenues and financial benefits from
its current portfolio, its development pipeline and restructuring
programmes.
These
planning assumptions as well as operating profit and earnings per
share guidance and dividend expectations assume no material
interruptions to supply of the Group’s products, no material
mergers, acquisitions or disposals, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made) and no
change in the Group’s shareholdings in ViiV Healthcare. The
assumptions also assume no material changes in the healthcare
environment or unexpected significant changes in pricing as a
result of government or competitor action. The 2024 guidance
factors in all divestments and product exits announced to
date.
Notwithstanding
our guidance, outlooks and expectations, there is still uncertainty
as to whether our assumptions, guidance, outlooks and expectations
will be achieved.
The
guidance is given on a constant currency basis.
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, and
expectations described in this report are achievable based on those
assumptions. However, given the forward-looking nature of these
guidance, outlooks, and expectations, they are subject to greater
uncertainty, including potential material impacts if the above
assumptions are not realised, and other material impacts related to
foreign exchange fluctuations, macro-economic activity, the impact
of outbreaks, epidemics or pandemics, changes in legislation,
regulation, government actions or intellectual property protection,
product development and approvals, actions by our competitors, and
other risks inherent to the industries in which we
operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
All
guidance, outlooks and expectations should be read together with
the guidance and outlooks, assumptions and cautionary statements in
this Q1 2024 earnings release and in the Group's 2023 Annual Report
on Form 20-F.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2023. Any forward-looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge and information available to the Directors
on the date of this report.
Independent review report to GSK plc
Conclusion
We
have been engaged by GSK plc (“the Company”) to review
the condensed financial information in the Results Announcement of
the Company for the three months ended 31 March 2024.
The
condensed financial information comprises:
|
|
|
|
●
|
the
income statement and statement of comprehensive income for the
three-month period ended 31 March 2024 on pages 23 and
24;
|
|
●
|
the
balance sheet as at 31 March 2024 on page 25;
|
|
●
|
the
statement of changes in equity for the three-month period then
ended on page 26;
|
|
●
|
the
cash flow statement for the three-month period then ended on page
27; and
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 28 to 37 that
have been prepared applying consistent accounting policies to those
applied by GSK plc and its subsidiaries (“the Group”)
in the Annual Report 2023, which was prepared in accordance with
International Financial Reporting Standards (“IFRS”) as
adopted by the United Kingdom.
|
We have
read the other information contained in the Results Announcement,
including the non-IFRS measures contained on pages 28 to 37 and
considered whether it contains any apparent misstatements or
material inconsistencies with the information in the condensed
financial information.
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial information in the Results
Announcement for the three months ended 31 March 2024 is not
prepared, in all material respects in accordance with the
accounting policies set out in the accounting policies and basis of
preparation section on page 34.
Basis for Conclusion
We
conducted our review in accordance with International Standard on
Review Engagements (UK) 2410 “Review of Interim Financial
Information Performed by the Independent Auditor of the
Entity” issued by the Financial Reporting Council for use in
the United Kingdom (ISRE (UK) 2410). A review of interim financial
information consists of making inquiries, primarily of persons
responsible for financial and accounting matters, and applying
analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with
International Standards on Auditing (UK) and consequently does not
enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit.
Accordingly, we do not express an audit opinion.
As
disclosed on page 34, the annual financial statements of the
Company are prepared in accordance with United Kingdom adopted
international accounting standards. The condensed set of financial
information included in this Results Announcement have been
prepared in accordance with the accounting policies set out in the
accounting policies and basis of preparation section on page
34.
Conclusion Relating to Going Concern
Based
on our review procedures, which are less extensive than those
performed in an audit as described in the Basis for Conclusion
section of this report, nothing has come to our attention to
suggest that the directors have inappropriately adopted the going
concern basis of accounting or that the directors have identified
material uncertainties relating to going concern that are not
appropriately disclosed.
This
Conclusion is based on the review procedures performed in
accordance with ISRE (UK) 2410, however future events or conditions
may cause the entity to cease to continue as a going
concern.
Responsibilities of the directors
The
directors are responsible for preparing the Results Announcement of
the Company in accordance with the Disclosure Guidance and
Transparency Rules of the United Kingdom’s Financial Conduct
Authority.
In
preparing the Results Announcement, the directors are responsible
for assessing the Company’s ability to continue as a going
concern, disclosing as applicable, matters related to going concern
and using the going concern basis of accounting unless the
directors either intend to liquidate the company or to cease
operations, or have no realistic alternative but to do
so.
Auditor’s Responsibilities for the review of the financial
information
In
reviewing the Results Announcement, our responsibility is to
express to the Company a conclusion on the condensed financial
information in the Results Announcement based on our review. Our
Conclusion, including our Conclusions Relating to Going Concern,
are based on procedures that are less extensive than audit
procedures, as described in the Basis of Conclusion paragraph of
this report.
Use of our report
This
report is made solely to the Company in accordance with ISRE (UK)
2410. Our work has been undertaken so that we might state to the
Company those matters we are required to state to it in an
independent review report and for no other purpose. To the fullest
extent permitted by law, we do not accept or assume responsibility
to anyone other than the Company, for our review work, for this
report, or for the conclusions we have formed.
Deloitte LLP
Statutory
Auditor
London,
United Kingdom
1 May
2024
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
1, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|